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Abstract
This report presents the results of the 2013 “EU Industrial R&D Investment Scoreboard” (the Scoreboard). The Scoreboard contains 
economic and financial data for the world’s top 2000 companies ranked by their investments in research and development 
(R&D). The sample consists of 527 companies based in the EU and 1473 companies based elsewhere. An additional sample 
comprising the top 1000 R&D investing companies based in the EU is included. The Scoreboard data are drawn from the latest 
available companies’ accounts, i.e. usually the fiscal year 2012 or 2012/13.
In this Scoreboard edition, world top R&D investors show a remarkable resilience of R&D investment growth in a period of 
economic uncertainty. In 2012, companies continued to increase significantly their R&D investments in a context marked by a 
slow-down of net sales growth and a decline in operating profits.
Trends observed show a significant variation of R&D investment and economic results across industries and sectors. This 
reflects persistent market uncertainties, in particular regarding the uneven potential for growth of international markets and the 
macroeconomic background.
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The 2013 “EU Industrial R&D Investment Scoreboard” (the 
Scoreboard) contains economic and financial data for the 
world’s top 2000 companies ranked by their investments 
in research and development (R&D). The sample contains 
527 companies based in the EU and 1473 companies based 
elsewhere. The Scoreboard data are drawn from the latest 
available companies’ accounts, i.e. usually the fiscal year 
2012 or 2012/131.
1 However, due to differences in accounting practices, the sampling period includes a 
range of dates from 2011 to early 2013  (see annex on methodological notes).
Summary
Key messages 
Trends observed show a significant variation in R&D investment and economic results across industries and sectors. 
This reflects persistent market uncertainties, in particular regarding the uneven potential for growth of international 
markets and the macroeconomic background. More salient facts observed from the analysis of 2012 and historic 
company data since 2003 include:
• A general remarkable resilience of R&D investment growth from top world R&D investors, in a period of economic 
uncertainty.
• The 527 EU companies featuring among the top world 2000 R&D investors in 2012 increased their investment in 
R&D by 6.3%, above world average (6.2%) but below the growth of their US counterparts (8.2%). EU overall positive 
numbers are largely driven by the R&D growth rates of German companies, particularly in the Automobile sector. 
• Volkswagen with €9.5bn invested in R&D leads the world R&D ranking. In second place is Samsung Electronics 
(€8.3bn) from South Korea.
• In addition to a good performance in the Automobiles & Parts sector, EU-based companies outperformed the R&D 
growth of their US counterparts in Industrial Engineering (12.3% vs. 9.4%) and Aerospace & Defence (9.5% vs. 
-1.3%).
• The US continues to increase its specialisation in the high R&D-intensive sectors of ICT and health. Among the top 
100 R&D investors, five ICT companies based in the US are among the best performers (increasing R&D and sales by 
more than 200% from 2004 to 2013). In the biotech sector, nine of the top ten companies are based in this country.
• An analysis of foreign direct investments (FDI) by the companies in the world R&D ranking shows that the EU plays, 
together with the US, a major role in the international investment scenario, both as a source and destination of 
cross-border R&D activities. From 2003 to 2012, the EU attracted 22% of FDI projects on R&D from the set of non-
EU companies.
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Top world R&D investors continued to increase their 
investment efforts in research and development 
significantly (6.2%) in 2012. This happened in a global 
context marked by a general slow-down of net sales 
growth (4.2% vs. 9.9% in 2011) and a decline in 
operating profits (-10.1%). 
During the three years following the financial crisis in 
2008-2009, Scoreboard companies increased their R&D 
investments by an average 6.2% per year (2010-2012). This 
resilience of companies’ R&D investments during a period of 
economic uncertainty reflects the strategic importance that 
companies attach to such investment. Figure S1 below shows 
the longer-term R&D trends for a subset of Scoreboard 
companies with available data for the past nine years.
Figure S1. One-year R&D investment and net sales growth in the Scoreboard
Note: For 1496 out of the top world 2000 companies in the Scoreboard with data for the whole period. 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
S u m m a r y
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The 527 EU companies featuring among the top world 
2000 R&D investors in 2012 are good exponents of 
sustained R&D focus in a challenging environment. 
Their R&D growth rate of 6.3% in 2012 is above the 4.3% 
growth rate of net sales, in a context of sharp profit decreases 
(-18.4%). This R&D growth rate is lower than that of their 
US counterparts (8.2%), which experienced a stronger slow-
down of net sales (2.9%). 
Following a much slower recovery after the crisis, in 2012 
top Japanese R&D investors showed some signs of recovery 
in net sales and profits, which are still not reflected in R&D 
growth figures (0.4%). Companies in the rest of the world 
continued to show high levels of R&D growth (8.8%).
For the EU, the US and Japan, respectively, figures S2-S4 
below show the longer-term R&D trends for subsets of 
Scoreboard companies with available data for the past nine 
years.
Figure S2. One-year R&D investment and net sales growth by EU companies
Note: For 334 out of the top EU 527 companies in the Scoreboard with data for the whole period. 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
Figure S3. One-year R&D investment and net sales growth by US companies
Note: For 547 out of the top US 658 companies in the Scoreboard with data for the whole period. 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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For the first time since 2004, a company based in 
the EU leads the world R&D ranking:  The German 
carmaker Volkswagen, with €9.5bn invested in R&D. 
Samsung Electronics from South Korea jumps to the 
second place.
The other companies in the top ten include five from the 
US (three pharma and two ICT), two from Switzerland (both 
pharma) and one from Japan (automobile). Most of the 100 
top companies showing the largest R&D increases continue 
to be, as in 2011, in the Automobiles & Parts and in the ICT 
sectors: e.g. Tata Motors, India (77.6%);  Fiat, Italy (51.5%); 
3M, the US (57.7%);  Western Digital, the US (49.0%); Apple, 
the US (39.2%); Volkswagen, Germany (32.1%); Qualcomm, 
the US (30.7%), Huawei, China (30.3%), Google, the US 
(27.7%). Some of these companies have increased R&D 
partly as a result of acquisitions.
The top 50 companies of the Scoreboard are mainly from 
Automobiles & Parts, 12 (13 in 2004), ICT industries, 14 (13 
in 2004) and Pharmaceuticals and Biotechnology, 15 (11 
in 2004). These companies are based in the EU, 16 (18 in 
2004), the US, 19 (17 in 2004) and Japan, 11 (same as in 
2004). 
Among the top 100 R&D investors, five ICT companies based 
in the US are among the best performers (in terms of R&D 
and sales growth) over the last ten years: Google (Internet), 
Oracle (Software), Qualcomm (Telecom equipment), Apple 
(Computer Hardware) and Broadcom (semiconductors).
The performance of EU companies compared to US 
companies in the ICT sectors varies by sub-sector... 
Despite lagging behind the US in the volume of R&D 
investments and in the number of companies, EU-based 
Scoreboard companies in the Software and Computer 
Services sector show very strong performance: 14.2% in 
R&D growth, coupled with 9.7% growth in sales (against 
12.6% and 6.9% respectively for the US). This contrasts with 
negative figures in the Technology Hardware & Equipment 
sector for EU companies (-2.3% in R&D and -9.3% in sales); 
very positive developments (14.8% and 6.8% respectively) 
are observed for US ones.
… while in the Automobiles & Parts, Industrial 
Engineering and Aerospace & Defence sectors, 
EU-based companies clearly outperform their US 
counterparts.
EU companies in the Automobiles & Parts sector, led by 
German carmakers in particular, show very high increases in 
R&D investment and sales (14.2% and 11.3% respectively). 
The R&D growth rates of Volkswagen (32.1%), BMW (17.2%) 
and Robert Bosch (17%) determine a large portion of 
German and EU overall positive numbers. The opposite holds 
true for US-based Automobiles & Parts companies (-2.6% 
for R&D and 0% for sales growth), still recovering from the 
crisis and the US government bail-outs of GM and Chrysler 
(now owned by Fiat). In the case of the Aerospace & Defence 
sector, strong regional differences in performance are also 
observed in favour of the EU: increases of 9.5% in R&D and 
8.3% in sales (against -1.3% and 6.7% respectively in the 
US).
The above-described divergent sectoral performances in the 
EU and US regions observed in 2012 point to a reinforcement 
of their relative specialisation: towards medium-high R&D-
Figure S4. One-year R&D investment and net sales growth by Japanese companies
Note: For 324 out of the top Japanese 353 companies in the Scoreboard with data for the whole period. 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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intensive sectors in the EU and towards high R&D-intensive 
sectors in the US (see figure S5).
Trends observed in the pharmaceutical and 
biotechnology subsectors illustrate well the 
reinforcement of the US specialisation towards high-
tech intensive sectors.
While in 2012 the performance of the pharmaceutical and 
biotech sector in the US slowed down, showing the negative 
effect of the expiration of several of their blockbuster patents 
(4.3% in R&D but -0.3% in sales, compared with 3.2% and 
2.8% respectively in the EU), the trend over the last ten years 
shows that the EU-US R&D investment gap in this sector is 
maintained (see figure S6).
A more detailed analysis of the therapeutic biotechnology 
subsector (expected to contribute with up to 50% of new 
drugs by 2018) shows the dominance of the US: eight of the 
top ten companies in terms of R&D growth and profitability 
are based in that country. However, evidence shows that 
there are a number of examples of EU companies which 
show both high performance and the ability to grow to a 
sustainable size through well-chosen collaborations, mainly 
with large pharmaceutical counterparts. 
Figure S5. R&D investment of EU and US companies by sector group
Note: For 350 EU and 566 US out of the top world 2000 companies in the  Scoreboard with data for the whole period. 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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An analysis of foreign direct investments (FDI) by the 
companies in the world R&D ranking shows that the 
EU attracted 22% of FDI projects on R&D from the set 
of non-EU companies.
The EU, together with the US, plays a major role in the 
international investment scenario, both as a source and 
destination of knowledge-intensive FDIs. From 2003 to 
2012, the EU attracted 22% of FDI projects on R&D from 
the set of non-EU companies while the US received only a 
share of 8 % (see figure S7). Six out of the ten countries with 
the highest number of international projects are European. 
FDIs in R&D are concentrated mainly in 3 sectors: IT Hardware, 
Automobiles & Parts, and Pharmaceuticals & Biotechnology.
Figure S6.  Relative size of EU R&D in Pharma and Biotech compared to US
Source: The 2013 EU Industrial R&D Investment Scoreboard European Commission, JRC/DG RTD.
Note: The relative size has been calculated as the ratio of sector R&D expenditures in EU over US considering the 136 companies with R&D data for 
the whole period.
Figure S7. Inflows of FDIs in R&D by main world regions 2003-2012
Data: FT fDi Markets database.
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
I n t r o d u c t i o n
11
In 2013, we continued implementing changes in the “EU 
Industrial R&D Investment Scoreboard” (the Scoreboard)2 
aiming to enhance its capacity to monitor and analyse 
worldwide trends in industrial R&D. For background 
information on the Scoreboard please see Annex 1.
The scope of the Scoreboard has improved progressively, 
increasing the geographic and time coverage and the number 
of companies. The target is to cover fast-growing medium-
sized companies, particularly those in key sectors such as 
health and the ICT-related industries.
Thus far, the total R&D investment of companies included in 
the Scoreboard is equivalent to more than 90% of the total 
expenditure on R&D by businesses worldwide3. 
In this year’s edition, the Scoreboard includes the 2000 
companies investing the largest sums in R&D in the 
world while maintaining an EU focus by complementing this 
coverage with the inclusion of the top 1000 R&D investing 
companies based in the EU4. 
The Scoreboard collects key information to enable the R&D 
and economic performance of companies to be assessed. 
The main indicators, namely R&D investment, net sales, 
capital expenditures, operating profits and number of 
employees are collected following the same methodologies, 
definitions and assumptions applied in previous years. This 
ensures comparability so that the companies’ economic and 
financial data can be analysed over a longer period of time. 
For the second year, data are now being collected by 
Bureau van Dijk Electronic Publishing GmbH, following 
basically the same approach and methodology applied 
since the first Scoreboard edition in 2004. Please see the 
main methodological limitations summarised in Box 1 and 
detailed methodological notes in Annex 2.
2  The EU Industrial R&D Investment Scoreboard is published annually by the European 
Commission (JRC-IPTS/DG RTD) as part of its Industrial Research and Innovation 
Monitoring and Analysis activity (IRIMA). 
3  According to the latest figures reported by Eurostat, i.e. BERD financed by the 
business enterprise sector in 2009 compared with R&D figures in the 2010 Scoreboard.
4  In this report, the term EU company refers to companies whose ultimate parent has 
its registered office in a Member State of the EU. Likewise, non-EU company applies 
when the ultimate parent company is located outside the EU (see also the glossary and 
definitions in Annex 2 as well as the handling of parent companies and subsidiaries).
The capacity of data collection is being improved by 
gathering information about the ownership structure of the 
Scoreboard parent companies and the main indicators for 
their subsidiaries. This will allow a better characterisation 
of companies, in particular regarding the sectoral and 
geographic distribution of their research and production 
activities and the related patterns of growth and employment.
Companies’ behaviour and performance can be analysed 
over longer time periods using our history database that 
contains information on the top R&D companies since 
2003. This enables benchmarking analyses of companies 
across sectors and countries, for example the identification 
of companies showing outstanding economic or innovation 
results and the analysis of the main factors underlying such 
successful dynamics.
In this year’s edition of the Scoreboard, companies’ 
R&D rankings are based on information taken from the 
companies’ latest published accounts. For most companies 
these correspond to calendar year 2012, but a significant 
proportion have financial years ending on 31 March 2013. 
There are few companies included with financial years 
ending as late as end June 2013 and a few for which only 
accounts to end 2011 were available.
This report concentrates on the analysis of the world’s 
top 2000 companies that all invested more than 
€22.6 million in R&D in 2012. The sample comprises 
companies based in the EU (527), the US (658), Japan 
(353) and other countries (462) including China, 
Taiwan, South Korea, Switzerland, the Cayman Islands, 
India, Canada, Australia, Israel, Norway, Bermuda, 
Brazil and a further 13 countries.  A sample consisting 
of the top 1000 R&D investing companies based in the 
EU is analysed separately in chapter 4; these all have 
R&D investments exceeding €5.2 million.
The characteristics of the sample of 2000 companies used 
for most of the analysis are summarised in Table 1.
The sector and country composition of the EU 1000 sample 
is found in Annex 3. 
This edition shows that companies continued to increase 
R&D investments in 2012 at a significant pace, higher than 
the growth rate of revenues. This report also shows a great 
Introduction
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variety in company R&D and economic patterns across 
industries and between countries, reflecting important 
differences in market conditions and economic background 
throughout the world. 
Report structure 
Chapter 1 presents the worldwide trends of industrial R&D. 
It provides an overview of the main indicators for the top 
2000 companies ranked by level of R&D investment and the 
main changes that took place over the last year. An analysis 
of the main indicators of the company data aggregated by 
world regions is included together with the performance of 
companies over the period 2004-2012.
The performance of individual companies among the top 
R&D investors is provided in chapter 2. The list of the top 
world 100 R&D companies is examined highlighting those 
companies showing remarkable R&D and economic results 
and improvement in the R&D ranking over the last 10 years.
Chapter 3 presents an analysis of the main R&D and 
economic indicators of companies aggregated by industrial 
sector, with comparisons of EU companies and their main 
worldwide counterparts. 
Chapter 4 discusses the trends on R&D and economic 
performance of the companies included in the extended 
sample comprising the top 1000 R&D investors based in 
Member States of the EU. 
Chapter 5 focuses on the analysis of R&D-led trends on 
health and biotechnology and the behaviour of the main 
industrial players included in the Scoreboard over the past 
10 years. The chapter includes the identification of most 
successful companies in this field and the comparison across 
countries and regions. 
Finally, chapter 6 presents an analysis based on data about 
foreign direct investments (FDIs) made by the Scoreboard 
companies. It covers FDIs committed to R&D projects as well 
as to production facilities and other industrial activities. It 
includes a comparison of companies’ FDI strategies across 
sectors and countries.  
Annex 1 provides background and methodological information 
about how the Scoreboard is prepared. The methodological 
approach of the Scoreboard, its scope and the limitations are 
described in Annex 2 and the listing of companies ranked by 
their level of R&D investment is provided in Annex 3.  
The complete data set is freely accessible online at: http://iri.
jrc.ec.europa.eu/scoreboard13.html
In the next edition, this website will allow user-friendly and 
interactive access to the individual company data or to 
groups of companies aggregated by industrial sector and 
country.  
Table 1.  Profile of the 2013 Scoreboard. 
2000 companies with R&D investment above €22.6 million
527 companies based in the EU
Companies by 
country
Germany 130;  United Kingdom 107;   France 75;   Sweden 40;   Netherlands 35;  Italy 30;  Denmark 25; 
Finland 20;   Spain 16;  Belgium 13;  Austria 12; Ireland 11; Luxembourg 4 ; Portugal 4 ; Czech Republic 
1 ; Greece 1;  Hungary 1; Malta 1; Slovakia 1 
The 10 most 
numerous 
sectors 
Industrial Engineering 62; Pharmaceuticals & Biotechnology 58; Electronic & Electrical Equipment 38; 
Software & Computer Services 37;  Automobiles & Parts 36; Technology Hardware & Equipment 29; 
Chemicals 24; Banks 23; Health Care Equipment & Services 20; Aerospace & Defence 18. The top 5 
sectors account for 43.8% of the 527.
1473 companies based in non-EU countries
Companies by 
country
US 658;   Japan 353;   China 93;  Taiwan 82;  South Korea 56;  Switzerland 54;  Cayman Islands 49;  India 
22;   Canada 17;  Australia 15;  Israel 15; Norway 11;  Bermuda 10;  Brazil 8 and further 13 countries.
The 10 most 
numerous 
sectors 
Technology Hardware & Equipment 264; Pharmaceuticals & Biotechnology 156;  Software & Computer 
Services 151;   Electronic & Electrical Equipment 139; Industrial Engineering 116; Chemicals 94; 
Automobiles & Parts 90; Health Care Equipment & Services 63; General Industrials 54;  Construction & 
Materials 39. The top 5 sectors account for 56.1% of the 1473.
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
I n t r o d u c t i o n
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Box 1  Methodological caveats
Users of Scoreboard data should take into account the methodological limitations summarised here,  especially when 
performing comparative analyses (full description of methodology is found in Annex 2): 
A typical problem arises when comparing data from different currency areas.  The Scoreboard data are nominal and 
expressed in Euros with all foreign currencies converted at the exchange rate of the year-end closing date (31.12.2012). 
The variation in the exchange rates from the previous year directly affects the ranking of companies, favouring those 
based in countries whose currency has appreciated with respect to the other currencies. In this reporting period, 
exchange rates of the Euro against main currencies changed less than in past years. The main currency move was due 
to the Japanese Yen that depreciated by 13.5% against the Euro, whereas the US dollar depreciated by less than 2.5% 
and the pound sterling remained practically unchanged. 
The growth rate of the different indicators for companies operating in markets with different currencies is affected 
in a different manner. In fact, companies’ consolidated accounts have to include the benefits and/or losses due to 
the appreciation and/or depreciation of their investments abroad. The result is an ‘apparent’ rate of growth of the 
given indicator that understates or overstates the actual rate of change. For example, this year the R&D growth rate 
of companies based in the Euro area with R&D investments in Japan is partly understated because the ‘losses’ of 
their overseas investments due to the appreciation of the Euro against the Japanese yen (from ¥100.6 to ¥114.2). 
Conversely, the R&D growth rate of Japanese companies is partly overstated due to the ‘benefits’ of their investments 
in the Euro area. Similar effects of understating or overstating figures would happen for other indicators, e.g. for net 
sales. 
When analysing data aggregated by country or sector, be aware that in many cases, the aggregate indicator depends 
on the figures of a few firms. This is due, either to the country’s or sector’s small number of firms in the Scoreboard or 
to the indicator dominated by a few large firms.
The different editions of the Scoreboard are not directly comparable because of the year-on-year change in the 
composition of the sample of companies, i.e. due to newcomers and leavers. Every Scoreboard comprises data of 
several financial years allowing analysis of trends for the same sample of companies.
In most cases, the companies’ accounts do not include information on the place where R&D is actually performed; 
consequently the approach taken in the Scoreboard is to attribute each company’s total R&D investment to the country 
in which the company has its registered office. This should be borne in mind when interpreting the Scoreboard’s country 
classification and analyses.
Growth in R&D can either be organic, the outcome of acquisitions or a combination of the two. Consequently, mergers 
and acquisitions may sometimes underlie sudden changes in specific companies’ R&D growth rates and/or positions 
in the rankings. 
Other important factors to take into account include the difference in the various countries’ (or sectors’) business cycles 
which may have a significant impact on companies’ investment decisions, and the initial adoption or stricter application 
of the International Financial Reporting Standards (IFRS)5. 
5 
5 Since 2005, the European Union requires all listed companies in the EU to prepare their consolidated financial statements according to IFRS (see: EC Regulation No 1606/2002 
of the European Parliament and of the Council of 19 July 2002 on the application of international accounting standards at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri
=CELEX:32002R1606:EN:HTML).
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This chapter provides an overview of changes in the main 
R&D and economic indicators of the world 2000 companies 
that invested more than €22.6 million in R&D in 20126. It 
comprises an analysis of the company data aggregated by 
main world region for the period 2004-2012.
This edition shows that companies continued to increase 
R&D investments in 2012 at a significant pace and well 
above the growth rate of revenues. 
Trends observed show a significant variation of R&D 
investment and economic results across industries and 
sectors and important differences with respect to the 
previous year. This reflects persistent market uncertainties, 
in particular regarding the uneven potential for growth of 
international markets and the macroeconomic background.
  
Key findings
• The top 2000 Scoreboard companies invested in R&D 6.2% 
more in 2012 than in 2011, following the increase of 6.1% 
in the year before. The net sales of the 2000 companies 
increased less than R&D, at 4.2%, compared with the net 
sales increase of 9.9% in 2011.
• The 527 EU companies increased R&D investment and 
net sales by the significant figures of 6.3 % and 4.3 % 
respectively. The 658 US companies reported a higher 
increase in R&D (8.2 %) but a much lower increase in net 
sales (2.9 %). The Japanese companies continued to lag 
behind, the 353 companies based in Japan increased R&D 
by only 0.4% and net sales by 3.3%. 
• Companies outside of the EU, the US and Japan (the OC 
group) continued to significantly increase R&D and net 
sales, by 8.8 % and 5.8 % respectively, but at a lower pace 
compared with previous years. The largest increases in 
R&D investment in this group were reported by companies 
6 Due to data availability some companies may be missed, please see methodological 
limitations in Annex 2.
based in China (12.2 %), South Korea (8.9 %) and Taiwan 
(8.2%).
• Trends over the past 8 years show that companies based 
in the EU and the US have recovered levels of R&D growth 
prior to the crisis whereas that of net sales, that recovered 
significantly in 2010-2011, fell well below the rate of R&D 
growth in 2012.
1.1 Indicator changes over the 
last year
The main economic and financial indicators for the year 2012 
for the set of 2000 companies are summarised in Table 1.1.
 
• After the recovery of company results showed last year, this 
year’s edition of the Scoreboard still shows a significant 
rise in worldwide R&D investment. The 2000 Scoreboard 
companies invested €538.8 billion in R&D, 6.2% more 
than in 2011, following the increase of 6.1% in the year 
before. Seventy per cent of the companies showed positive 
R&D growth in 2012.  
• For the second consecutive year, the net sales of the 
2000 companies increased less than R&D, at 4.2%, less 
than the net sales increase of 9.9% in 2011.  Company 
results in terms of operating profits were mixed, 82% of 
the companies made profits and average profitability was 
9.2%, however the remaining companies (18%) presented 
strong losses.
• Company investment in fixed capital continued to grow at 
a significant pace. It increased by 9.6% compared with the 
previous year’s increase of 12.7%. Capital expenditure as 
a percentage of net sales increased slightly from 6.6% in 
2011 to 7.1% in 2012.
1 Worldwide trends in corporate 
R&D
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1.2 R&D trends by world region
7 8
This section analyses the overall R&D and economic 
performance of the Scoreboard companies according to the 
location of their registered offices in the main world regions. 
The 2000 companies are grouped into four main sets: the top 
527 companies from the EU, 658 companies from the US, 
353 from Japan and 462 companies from other countries 
(OC). ‘Other countries’ includes companies from China (93), 
Taiwan (82), South Korea (56), Switzerland (54), the Cayman 
Islands (49), India (22) and companies based in a further 19 
countries.
Figure 1.1 and table 1.2 summarise the companies’ indicators 
aggregated by main world region. Table 1.3 shows the main 
indicators for countries included in the OC group.
The R&D investment and net sales for the 527 EU companies 
continued to grow at significant pace in 2012, at 6.3 % and 
4.3 % respectively (slightly above the world’s average of 6.2 
% and 4.2 % respectively). 
The positive overall numbers of the EU group are largely driven 
by the performance of German companies, particularly in the 
Automobiles & Parts sector. The 130 German companies, 
with an R&D share of 34% in the EU group, increased R&D 
7 Compound annual growth rate.
8 Fixed capital investment.
by 11.9% contributing more than 60% of the R&D growth of 
the EU companies.  
The group of US companies increased R&D investment 
significantly above the world’s average, at 8.2 % but net 
sales only grew by 2.9 % compared with a strong increase 
in 2011. 
Japanese companies underperformed against EU firms, both 
in terms of R&D and net sales, increasing R&D investments 
and net sales only by 0.4% and 3.3% respectively. 
Companies based outside of the EU, US and Japan (the 
OC group) substantially increased R&D and net sales, by 
8.8 % and 5.8 % respectively, but in a lesser proportion 
than in previous years, especially in terms of net sales. The 
largest increase in R&D investment was reported by the 
93 companies based in China (12.2 %), although the total 
R&D of these companies is still modest (3.0% of the total 
sample). Other companies in this group that showed large 
increases in R&D were companies based in the Cayman 
Islands (38.7%), India (33.1%), South Korea (8.9%) and 
Taiwan (8.2%). The companies based in Switzerland, the 
largest R&D investing country of the OC group (world R&D 
share of 4.2%) increased R&D in 2012 by 4.3%. Two large 
Swiss companies, Roche and Novartis, dominate the R&D 
figures of their home country with 62% of Swiss R&D.
Compared with last year’s Scoreboard (1500 top R&D 
investors), the EU companies’ share of total R&D investment 
rose by 1.2 (from 28.3 % to 29.5 %).  The share held by 
US companies increased slightly by 0.5 percentage points, 
Table 1.1 Overall performance of the 2000 companies in the 2013 Scoreboard 
Factor World-2000
R&D investment, € bn
One-year change, %
CAGR7 3yr, %
538.8
6.2
6.4
Net Sales, € bn
One-year change, %
CAGR  3yr, %
16845.8
4.2
8.5
R&D intensity, % 3.2
Operating profits,  € bn
One-year change , %
Profitability, %
1549.3
-10.1
9.2
Capex8, € bn
Capex / net sales, %
One-year change , %
1109.1
7.1
9.6
Number of employees, million
One-year change, %
48.471
1.5
Note: Calculation of growth rates and ratios include only companies for which data are fully available.
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
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companies based in other countries (OC) increased their 
share by 1.2 percentage points, while the share of Japanese 
companies fell sharply by 2.9 points. 
The average R&D intensity of the EU, US and OC companies 
increased due to a higher growth of R&D investments 
compared with the growth rate of net sales, especially for 
the US companies that had the lowest growth rate of net 
sales. On the contrary, companies based in Japan decreased 
their average R&D intensity because of their very low growth 
rate of R&D compared to that of net sales. 
Company figures for fixed capital expenditure changed 
significantly over the last year. Companies based in the EU 
recovered substantial levels of investment (9.8% growth) 
compared with a slight decrease in the previous year.  The 
US and Japanese companies substantially increased their 
fixed capital expenditures to 11.7 % and 13.9 % respectively, 
whereas that of companies from the OC group increased at 
a more modest rate (5.7 %).      
Companies in three of the four regions decreased profits in 
2012 with Japanese companies showing a 4.2% increase 
but the EU had the largest decrease. As a consequence of 
this, the profitability (operating profits as percentage of net 
sales) remained level for Japan, decreased a little for the US 
but decreased a lot for the EU (the effect of a low growth 
rate of net sales can be offset by a lower growth rate of 
profits). In the case of the US group of companies, the drop in 
profits partially reflects the major losses of General Motors, 
which has just emerged from bankruptcy. In fact, this year’s 
accounts for General Motors include a “goodwill impairment 
charge” of $27bn and related losses of $30.4bn.  
As underlined in previous editions, most of the differences 
in R&D intensity and profitability between regions and 
countries are related to differences in sector mix. The 
US is by far the strongest region in the group of high 
R&D intensity sectors including pharmaceuticals, health, 
software, and technology hardware whereas the EU and 
Japan are stronger in medium R&D intensity sectors like the 
automotive sector (see chapter 4).
Figure 1.1  R&D investment by the top 2000 companies, by main world region (% of total €538.8bn)
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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Table 1.2  Overall performance of the 2000 companies in the 2013 Scoreboard
Factor EU USA Japan Other countries
No. of companies 527 658 353 462
R&D in 2012, € bn 158.0 189.4 102.7 89.4
World R&D share, % 29.3 35.2 18.9 16.6 
One year change, % 6.3 8.2 0.4 8.8 
CAGR 3yr, % 6.4 8.0 1.2 9.4 
 Net Sales, € bn 5974.6 3892.2 2944.0 4039.9
One year change, % 4.3 2.9 3.3 5.8 
CAGR 3yr, % 8.6 8.4 3.0 13.0 
R&D intensity, % 2.6 4.9 3.5 2.2 
Operating Profit, € bn 483.4 505.7 131.1 429.0
One year change, % -18.4 -5.5 4.2 -8.9 
Profitability9 8.1 13.0 4.4 10.6 
Capex, € bn 361.90 231.3 195.2 320.7
Capex intensity 7.1 6.0 6.6 8.8 
One year change, % 9.8 11.7 13.9 5.7
Employees, million 18.357 11.138 8.206 10.770
One year change, % 1.1 3.0 1.3 1.0
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
9
Table 1.3  Overall performance of companies based in the largest countries of the OC (other countries) group 
in terms R&D
Factor Switzerland South Korea China Taiwan  OC group
No. of companies 54 57 93 82 462
R&D in 2012, € bn 22.4 17.5 16.1 9.3 89.4
World R&D share 4.2 3.3 3.0 1.7 16.6
One year change, % 4.3 8.9 12.2 8.2 8.8
CAGR  3yr, % 0.8 7.5 22.9 8.9 9.4
R&D intensity 6.4 2.2 1.4 2.2 2.2
Profitability 15.4 6.6 6.6 3.4 10.6
Employees, thousand 1375.8 1.6* 4152.2 2112.0 10770.0
One year change, % 5.1 -77.3* -0.4 -1.8 1.0
* Many South Korean companies do not report number of employees.
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
9 Operating profits as percentage of sales.
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1.2.1 Long-term performance of companies by world 
region
The annual growth rates of R&D investment and net sales 
and the profitability of companies based in the EU, the US 
and Japan is provided respectively in figures 1.2, 1.3 and 1.4 
for the period 2004-2012. These figures are based on our 
history database comprising R&D and economic indicators 
over the whole 2004-2012 period for 1017 companies (EU 
248, US 358 and Japan 241).
The trends observed in these figures show the behaviour 
of these companies including the effects of the crisis that 
began in 2008. The following points are observed:
• In terms of R&D growth, companies based in the EU and 
the US seem to have recovered to the levels prior to the 
crisis, whereas Japanese companies lag behind, probably 
because of special adverse factors such as the earthquake.
• The growth rate of net sales for companies based in the 
EU and the US was hit hard by the crisis in 2008-2009 
but recovered strongly in 2010-2011 with EU companies 
outperforming US firms in 2012. Net sales of companies 
from Japan were somewhat less affected by the crisis in 
2008-2009 but have shown a slow recovery in the past 
two years.
• Performance in terms of profitability show that US-based 
companies recover more rapidly from the crisis and have 
Figure 1.2 One-year R&D investment and net sales growth and profitability by the EU companies
Note: For 388 EU out of the 2000 companies with R&D and net sales data for the whole period 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
Figure 1.3 One-year R&D investment and net sales  growth and profitability by the US companies
Note: For 547 US  out of the 2000 companies with R&D and net sales data for the whole period 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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higher levels of profitability than their EU counterparts and 
are especially higher than the Japanese ones.
1.2.2 R&D trends by world regions and sector groups  
Trends in R&D over the long-term are presented in figure 
1.5 for the main world regions. The figures refer to a set of 
companies that reported R&D over the whole period 2004-
2012 (1559 companies: EU 352, US 564, Japan 332 and rest 
of the world 311). The R&D data are broken down into groups 
of industrial sectors with characteristic R&D intensities (see 
definition in Box 1.1). 
The following points can be observed regarding the overall 
R&D changes in the period 2004-2012 (figure 1.6): 
• The world 1559 companies increased R&D by 50.8% (EU-
352 44.4%; US-564 66.2%; Japan-332 11.6% and rest of 
the world-311 124.8%).
• For the 352 EU companies, the main R&D increases were 
in low R&D-intensive sectors (50.3%) and medium-low 
sectors (46.6%).   
• For the 564 US companies, the main R&D increases were 
in medium-low R&D-intensive sectors (125.7%) and high 
sectors (79.7%). 
• For the 332 Japanese companies, the main R&D increases 
were in medium-high R&D-intensive sectors (12.8%) and 
high sectors (12.3%). 
• For the 311 companies based in the rest of the world, the 
main R&D increases were in low R&D-intensive sectors 
(276.7%) and high sectors (129.1%). 
Figure 1.4 One-year R&D investment and net sales growth and profitability by the Japanese  companies
Note: For 547 US out of the 2000 companies with R&D and net sales data for the whole period 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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Box 1.1 Grouping of industrial sectors according to R&D intensity (R&D as % of net sales)
High R&D intensity sectors (intensity above 5%) include e.g. Pharmaceuticals & biotechnology; Health care 
equipment & services; Technology hardware & equipment; Software & computer services and Aerospace & 
defence.
Medium-high R&D intensity sectors (between 2% and 5%) include e.g. Electronics & electrical equipment; 
Automobiles & parts; Industrial engineering & machinery; Chemicals; Personal goods; Household goods; 
General industrials; Support services.
Medium-low R&D intensity sectors (between 1% and 2%) include e.g. Food producers; Beverages; Travel 
& leisure; Media; Oil equipment; Electricity; Fixed line telecommunications.
Low R&D intensity sectors (less than 1%) include e.g. Oil & gas producers; Industrial metals; Construction 
& materials; Food & drug retailers; Transportation; Mining; Tobacco; Multi-utilities.
Figure 1.5 R&D investment trends by the Scoreboard companies for main world regions
Note: For companies that reported R&D for the whole period 2004-12 (EU-352, US-564, Japan-332 and Rest of the World-311). 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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1.2.3 Employment trends by regions and sector groups
The companies listed in this year’s Scoreboard employed 
48.471 million people in 2012, 1.5% more than the previous 
year. The distribution of employees by region was 18.357 
million in the 527 companies based in the EU, 11.138 million 
in the 658 US companies, 8.206 million in the 353 Japanese 
companies and 10.770 million in the 462 companies from 
other countries (1827 out of the 2000 companies reported 
number of employees).
Trends on employment over the long-term are presented in 
figure 1.6 for the main world regions. The figures refer to a set 
of companies that reported number of employees over the 
whole period 2004-2012 and are broken down into groups 
of industrial sectors with characteristic R&D intensities (see 
definition in Box 1.1). 
The following points can be observed regarding the changes 
in number of employees in the period 2004-2012 (figure 
1.6):
 
• Overall worldwide employment increased by 27.9 % from 
2004 to 2012 led by increases in high R&D-intensive 
sectors (42.0 %) and medium-high sectors (29.9 %).
• For the EU companies, the overall employment growth 
was 22.6 %, increasing by 49.2 % in high R&D-intensive 
sectors, by 24.2% in medium-high and by 18.5% in low 
sectors.
• For the US companies, the overall employment growth 
(25.1 %) greatly varies by sector group: a strong increase 
for high R&D-intensive sectors (43.7 %) and a sharp 
decrease in low-tech sectors (-23.2 %).
• For the Japanese companies, the overall employment 
increase of 24.0 % corresponded to an increase of 31.4 
% in low R&D-intensive sectors and of 28.5 % in medium-
high sectors.
• The ratio of employment in high to medium-high R&D 
intensity sectors for companies based in Japan fell from 
38% to 32%, rose slightly for EU companies, from 29% 
to 35%, and went up a lot for US companies from 80% to 
98%. This illustrates the way high R&D-intensive sectors 
in the US have been growing rapidly while medium-high 
sectors such as the automotive sector are slowly going 
down the rankings.
It is important to remember that data reported by the 
Scoreboard companies do not inform about the actual 
geographic distribution of the number of employees. A 
detailed geographic analysis should take into account the 
location of subsidiaries of the parent Scoreboard companies 
as well as the location of other production activities involved 
in the value-chains.
Figure 1.6  Employment trends by the Scoreboard companies for main world regions.
Note: For 1295 out of the EU, US, and Japanese companies and those from the Rest of the World that reported employment data for the whole period 
2004-12. 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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This chapter describes the performance of individual 
companies, with a focus on the results of top R&D investors, 
highlighting those companies that show considerable 
changes in economic performance, in particular from an R&D 
viewpoint.
The world’s top 100 R&D companies are analysed, highlighting 
those presenting important changes from the previous year 
and those showing the best performance in terms of R&D 
and economic growth over the last 10 years. This year’s R&D 
ranking of the top 50 companies is presented in figure 2.1 
and table 2.1 shows changes in such ranking since the first 
Scoreboard in 2004.
Key findings
• The top R&D investor is the German company Volkswagen, 
which was in 3rd place last year and in 6th place the 
year before. In 2nd position is Samsung Electronics from 
South Korea with Microsoft from the US 3rd.  The other 
companies in the top-ten include four from the US, two 
from Switzerland and one from Japan.
• Results of the top 100 companies, accounting for 54.6 % of 
the total R&D investment by the 2000 companies, confirm 
the continued recovery of industrial R&D investment. Of 
these 100 companies, 72 increased R&D investment (vs. 
75 in 2011), including 30 companies with double-digit 
R&D growth; of the 28 that decreased R&D, 7 decreased 
by a double digit percentage. Regarding net sales, 64 
companies reported an increase (vs. 71 in 2011), including 
25 companies with double-digit sales growth.
• The top 100 group includes:
 ₋ 28 EU companies of which 19 have increased R&D (10 
by more than 10%), 
 ₋ 37 US companies of which 31 increased R&D (11 by 
more than 10%), 
 ₋ 22 from Japan of which 10 increased R&D (4 by more 
than 10%) and 
 ₋ 14 companies from other countries of which 12 
increased R&D (5 by more than 10%).
• The companies showing the largest increase in R&D are 
Tata Motors, India (77.6%); 3M, US (57.7%); FIAT, Italy 
(51.5%); Western Digital, US (49.0%); Gilead Sciences, US 
(46.4%).  Those showing the largest decrease in R&D are 
Renesas, Japan (-24.9%); Hitachi, Japan (-17.3%); Boeing, 
US (-17.1%); Nokia, Finland (-15.1%); Pfizer, US (-14.0%).
• Among the top 100 group, 30 companies have at least 
doubled their net sales since 2004 (8 companies based 
in the EU and 13 from the US). This group of companies 
is mainly from high R&D-intensive sectors (18); 27 of 
them have increased R&D by more than 100% and 15 
companies increased employment by more than 100%. A 
number of the large increases are for companies that have 
made substantial acquisitions.
General trends
In the 2013 Scoreboard 111 companies have an R&D 
investment of more than € 1.0bn (31 from the EU and 40 
from the US) while 55 have R&D exceeding € 2.0bn (18 from 
the EU and 21 from the US).
The top 10 companies invested more than € 5bn in R&D and 
account for 13.3 % of the total R&D investment by the 2000 
Scoreboard companies.
This year, the top R&D investor is the German company 
Volkswagen (€ 9.5bn) which was third last year and sixth in 
201010. There are five US companies in the top ten: Microsoft 
(€7.9bn), Intel (€7.7bn), Merck US (€6.0bn), Johnson & 
Johnson (€5.8bn) and Pfizer (€5.7bn). The other companies 
in the top ten are Roche (€ 7.0bn) and Novartis (€ 6.9bn) 
from Switzerland, Samsung Electronics (€8.3bn) from South 
Korea and Toyota Motor (€7.1bn) from Japan.
The top 100 companies invested € 295.4 billion, accounting 
for 54.6 % of the total R&D investment by all the 2000 
Scoreboard companies, although accounting for only 27.1% 
of the total net sales of the sample. The EU has 28 companies 
among the top 100 R&D investors, one company less than 
it had in the 2012 Scoreboard. The US has 36 companies, 
10 This year, the figures of VOLKSWAGEN include those of its new subsidiary PORSCHE 
that in 2011 reported €1046 of R&D investment. This amount of R&D accounts 
approximately for 50 % of the VOLKSWAGEN’s increase of R&D in 2012.   
2 Top R&D investing companies
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two more than it had last year and Japan has 22, three 
companies less than in last year’s Scoreboard.
The EU companies in the top 100 are mainly from the 
Automobiles & Parts (8), Pharmaceuticals & Biotechnology 
(7) and ICT sectors (5). The US companies are mainly 
from the ICT (13), Pharmaceuticals & Biotechnology (10), 
and Chemicals (3) sectors. The Japanese companies 
operate mainly in the Automobiles & Parts (5), ICT (4) and 
Pharmaceuticals (4) sectors.
Seventy-one companies in the top 100 have shown positive 
R&D investment growth. Among them, 30 companies had 
double-digit R&D growth, and of these, 17 companies also 
showed double-digit growth in net sales.  
Most of the top 100 companies showing the largest R&D 
increases are in the Automobiles & Parts sector, e.g. Tata 
Motors, India (77.6%);  Fiat, Italy (51.5%); Volkswagen, 
Germany (32.1%); BMW, Germany (17.2%), Bosch, Germany 
(16.1%) and in ICT sectors, e.g. 3M, US (57.7%); Western 
Digital, US (49.0%); Apple, US (39.2%); Qualcomm, US 
(30.7%), Huawei, China (30.3%), Google, US (27.7%).
Other companies among the top 100 group have shown 
double-digit growth in both R&D and net sales, e.g. Gilead 
Sciences and EBay from the US; SAP from Germany; Novo 
Nordisk from Denmark; Samsung Electronics from South 
Korea.   
Twenty-eight companies in the top 100 have experienced a 
decrease in R&D investing. Among these, three companies 
decreased R&D investments and net sales by more than 
10 %:  Renesas, Japan; Nokia, Finland and Vale, Brazil.
The R&D intensity of companies in the top 100 (6.4%) has 
increased slightly due to a higher rate of increase for R&D 
(6.2 %) than for net sales (5.7 %). The EU companies in the 
top 100 have a higher average R&D intensity (6.9 %) than 
that of non-EU companies (6.2 %). 
R&D changes driven by Mergers and Acquisitions 
(M&As)
The growth in R&D investment may either be organic or 
driven by M&As, or it may be a combination of the two. 
M&As (or demergers) may take place within or between 
regions/sectors and can significantly impact the ranking of 
companies in the Scoreboard. While acquisitions are not 
systematically captured in this report, some examples that 
had a significant effect on companies in the top positions are 
provided in table 2.1 below.   
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Long-term performance of top R&D companies
This section analyses the behaviour of the top companies 
over the last 10 years based on our history database 
containing company data for the period 2002-2012.  Results 
of companies showing outstanding R&D and economic 
results are underlined. 
Ranking of the top 50
Table 2.2 shows the evolution of the R&D rankings of the 
top 50 companies since the first Scoreboard in 2004 and 
the most important changes are highlighted. It is important 
to note, as stated in the previous section and in past reports, 
that the growth of companies is often accompanied by 
mergers and acquisitions. 
There are 16 EU companies (18 in 2004) and 34 non-EU 
companies (32 in 2004). In the EU group, three companies 
left the top 50 (Philips, Renault and BAE Systems) and one 
company joined the top 50 (Boehringer Ingelheim). In the 
non-EU group, eight companies left the top 50 (Fujitsu, 
Matsushita Electric, NEC, Motorola, Nortel Networks, Wyeth, 
Delphi, Sun Microsystems) and ten companies joined the top 
50 (Abbott, Amgen, Apple, Denso, Google, Huawei, Oracle, 
Panasonic, Qualcomm and Takeda Pharmaceuticals).
The distribution of the top 50 companies by main industrial 
sector and region changed from 2004 to 2012 as follows:
• Automobiles & Parts, from 13 (EU 7) to 12 (EU 6)
• ICT industries,  from 13 (EU 3) to 14 (EU 3)
• Pharma & Biotech, from 11 (EU 3) to 15 (EU 5)
The EU companies that improved by at least 10 places are 
Boehringer Ingelheim (now ranked 41st) and Sanofi (now 
15th). The latter was created after 2004 and is an example 
of R&D growth driven by M&As. 
There are 15 non-EU companies that gained more than 10 
places. They include Google, up more than 200 (now 13th), 
Panasonic, up 128 (now 19th), Qualcomm, up 87 (now 37th), 
Huawei, up more than 200 (now 31st), Oracle, up 40 (now 
29th). 
Companies which dropped ten or more places but remained 
within the top 50 include Siemens (now 17th), IBM (now 21st), 
Ford Motor (now 23rd), Ericsson (now 28th), NTT (now 49th), 
Hewlett-Packard (now 44th), and Nokia (now 22nd). 
Best performers among the top 100
Among the top 100 group, 14 companies have simultaneously 
increased R&D and net sales by more than 200% since 2004 
while showing positive operating profits in the last reporting 
period. Nine of these companies are based in the US, two 
in China and one each in Taiwan, India and Brazil (see table 
2.3). 
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Figure 2.1 The world’s top 50 companies by their total R&D investment (€m) in the 2013 Scoreboard
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
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Table 2.2 R&D ranking of the top 50 companies in the 2004 and 2013 Scoreboards
Rank in 2012 Company Rank change 2004-2012
1 VOLKSWAGEN up 7
2 SAMSUNG ELECTRONICS up 31
3 MICROSOFT up 10
4 INTEL up 10
5 TOYOTA MOTOR down 1
6 ROCHE up 11
7 NOVARTIS up 13
8 MERCK US up 21
9 JOHNSON & JOHNSON up 3
10 PFIZER down 8
11 DAIMLER down 8
12 GENERAL MOTORS down 6
13 GOOGLE up > 200
14 ROBERT BOSCH up 12
15 SANOFI up 40
16 HONDA MOTOR nil
17 SIEMENS down 13
18 CISCO SYSTEMS up 13
19 PANASONIC up 128
20 GLAXOSMITHKLINE down 9
21 IBM down 12
22 NOKIA down 12
23 FORD MOTOR down 22
24 SONY down 9
25 NISSAN MOTOR up 9
26 ELI LILLY up 15
27 BMW up 1
28 ERICSSON down 11
29 ORACLE up 42
30 EADS up 5
31 HUAWEI up > 200
32 GENERAL ELECTRIC up 5
33 ASTRAZENECA down 8
34 FIAT up 10
35 ABBOT LABORATORIES up 17
36 BAYER down 4
37 HITACHI down 13
38 QUALCOMM up 99
39 DENSO up 13
40 BRISTOL-MYERS SQUIBB up 2
41 TAKEDA PHARMACEUTICAL up 31
42 BOEHRINGER INGELHEIM up 20
43 TOSHIBA down 13
44 CANON down 5
45 HEWLETT-PACKARD down 22
46 APPLE up 109
47 AMGEN up 9
48 PEUGEOT (PSA) down 10
49 ALCATEL-LUCENT down 32
50 NTT down 29
Note : Companies in “blue” went up more than 20 ranks and companies in “red” lost more than 20 ranks.
Source: The EU Industrial R&D Investment Scoreboards 2013 and 2004.
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Table 2.3 Ranking of companies among the top 100 R&D investors that achieved the best performance over 
the last 10 years*
Rank Company Country Sector R&D in 2012(€ m)
1 GOOGLE USA Internet 4997.0
2 ORACLE USA Software 3675.9
3 QUALCOMM USA Telecommunications Equipment 2967.3
4 APPLE USA Computer Hardware 2562.5
5 BROADCOM USA Semiconductors 1756.9
6 PETROCHINA China Oil & Gas Producers 1741.6
7 TATA MOTORS India Automobiles & Parts 1496.0
8 EBAY USA General Retailers 1408.2
9 GILEAD SCIENCES USA Biotechnology 1333.9
10 CELGENE USA Biotechnology 1205.8
11
HON HAI PRECISION 
IND.
Taiwan Electronic Equipment 1191.6
12 WESTERN DIGITAL USA Computer Hardware 1191.5
13 ZTE China Telecommunications Equipment 1170.5
14 VALE Brazil Mining 1120.2
* These companies increased simultaneously R&D investment and net sales by more than 200 % from 2004 to 2012 and had positive operating prof-
its in 2012.
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
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This chapter presents the main R&D trends among Scoreboard 
companies aggregated by industrial sectors11. It comprises 
the ranking of sectors by their level of R&D investment, R&D 
intensities, rates of R&D growth and the comparison of such 
trends across world regions.
 
Key findings
• Companies from three out of the top five sectors by 
level of R&D investment increased R&D above the world 
average of 6.2%, namely Software & Computer Services 
(11.7%), Automobiles & Parts (8.9%) and Technology 
Hardware & Equipment (8.8%). The top R&D investing 
sector, Pharmaceuticals and Biotechnology achieved a 
more modest 4.1% increase of R&D. Other sectors that 
showed high R&D growth were the Industrial Engineering 
(9.8%) and Health Care Equipment & Services (8.3%) 
sectors.
• Companies based in the EU had the highest R&D growth 
in Automobile & Parts (14.4%), Software & Computer 
Services (14.2%) and the Industrial Engineering (12.3%) 
sectors. 
• Trends observed in the Scoreboard over the last 10 years 
show a characteristic sector specialisation by region. 
The largest R&D shares of the companies based in the 
EU are in Automobiles & Parts (24.9%), Pharmaceuticals 
& Biotechnology (17.5%) and Technology Hardware 
& Equipment (10.2%). The main R&D shares of those 
based in the US specialise in high R&D-intensive sectors, 
namely Technology Hardware & Equipment (25.2%), 
Pharmaceuticals & Biotechnology (22.1%) and Software 
& Computer Services (18.2%). These three high R&D-
intensity sectors account for 65.5% of US R&D, 30% for 
the EU and 26% for Japan.
General R&D trends
Figure 3.1 shows the R&D rankings of companies from the 
main industrial sectors including the relative R&D share 
11 According to the Industry Classification Benchmark (ICB) applied in the Scoreboard.
by main world region. The specialisation of the main world 
regions, represented by the share of sectors within the 
regions’ total R&D investment, is given in figure 3.2.
• R&D investment in the Scoreboard remains highly 
concentrated by sectors: Out of 40 industrial sectors, the 
top three –Pharmaceuticals & Biotechnology, Technology 
Hardware & Equipment and Automobiles & Parts– account 
for 50.2% of the total R&D investment by the Scoreboard 
companies; the top 6 and top 15 sectors constitute, 
respectively, 71.0% and 92.1% of the total R&D in the 
Scoreboard. A similar concentration of R&D by industrial 
sector has been observed over the last 10 years.
• The ranking of the top 15 sectors has changed as follows: 
The Industrial Engineering sector took over the 6th position 
from the Chemicals sector (now 7th), the General Industrials 
sector took the 9th position from the Leisure Goods (now 
10th).
• The Pharmaceuticals & Biotechnology sector keeps the 
first position in the R&D ranking, slightly increasing its R&D 
share of the total R&D investment which is now 18.1%. 
It is followed by the Technology Hardware & Equipment 
sector with a share of 16.4% (similar to last year’s 16.6%) 
and the Automobile & Parts sector with 15.7%, slightly 
higher than the 15.0% of last year.
• The R&D specialisation (share of R&D investment) of the 
main regions in the top 3 sectors are: 
 In the EU, Automobiles & Parts (24.9%), Pharmaceuticals 
& Biotechnology (17.5%), and Technology Hardware & 
Equipment (10.2%); 
 In the US, Technology Hardware & Equipment (25.2%), 
Pharmaceuticals & Biotechnology (22.1%) and Automobiles 
& Parts (6.6%);
  In Japan, Automobiles & Parts (26.4%), Pharmaceuticals 
& Biotechnology (10.8%) and Technology Hardware & 
Equipment (7.3%).
3 R&D distribution by industrial 
sector
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• The contribution to the total Scoreboard R&D by EU 
companies is 53.0% to Aerospace & Defence, 46.1% 
to Automobiles & Parts and 39.5% to the Industrial 
Engineering sectors; the US contributes 74.4% to Software 
and Computer Services, 63.8% to Health Care Equipment & 
Services and 54.0% to Technology Hardware & Equipment 
and; Japan contributes 34.5% to Chemicals, 33.3% to 
the Electronic & Electric Equipment sector and 31.8% to 
Automobiles & Parts.
R&D growth by industrial sector
The actual contribution of an industrial sector to the overall 
R&D growth of a region depends on its rate of R&D change 
and the sector’s share of total R&D of the region. Figures 3.1 
and 3.2 show the shares of the main industrial sectors and 
table 3.1 shows their ranking by R&D annual growth rate 
worldwide for the Scoreboard companies based in the main 
world regions (EU-527, US-658, and Japan-353).
The following points are observed for the top 15 sectors 
accounting for 92.1% of the total R&D investment of the 
Scoreboard companies:
• Worldwide, the Software & Computer Services sector 
shows the highest one-year growth rate (11.8%), followed 
by Industrial Engineering (9.8%), Automobiles & Parts 
(8.9%) and Technology Hardware & Equipment (8.8%) 
sectors.
• Among the companies based in the EU, the Automobiles & 
Parts sector shows the highest one-year growth rate (14.4 
%), followed by the Software & Computer Services (14.2 
%) and Industrial Engineering (12.3 %) sectors. Sectors 
showing the lowest one-year R&D growth are Banks 
(for which only the EU companies report R&D, -6.8 %), 
Fixed Line Telecom (-4.6%), and Technology Hardware & 
Equipment (-2.3 %).
• Among the companies based in the US, the Technology 
Hardware & Equipment sector shows the highest one-year 
growth rate (14.8 %) followed by Software & Computer 
Services (12.6 %) and Industrial Engineering (9.4%). 
Sectors showing the lowest one-year R&D growth are Food 
Producers (-12.4 %) and Leisure Goods (-4.6 %). 
• For Japanese companies, the highest one-year growth rate 
is shown by Automobiles & Parts (6.4 %) and Health Care 
Equipment & Services (4.9 %). The poorest performance 
was shown by General Industrials (-9.7 %) and Electronic 
& Electrical Equipment (-6.9 %).
Apart from the top 15 industries, there were important R&D 
changes in some other sectors:
• The alternative energy sub-sector that has shown a 
substantial increase of R&D investment over the past 
years sharply reduced R&D in 2012 (-26.1 %).
• Other sectors showing considerable R&D growth are Food 
& Drug Retailers (48.0 %) and Industrial Transportation 
(30.3%).
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Figure 3.1 R&D ranking of industrial sectors and share of main world regions for the world’s top 2000 
companies
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
Figure 3.2 R&D shares of sectors of the main world regions
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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Table 3.1 Ranking of top 15 industrial sectors by overall one-year R&D growth for the EU, US and Japanese 
companies in the 2013 Scoreboard
Rank Sector
Overall 
one-year R&D 
growth (%)
EU-527 
R&D change 
(%)       
US-658
R&D change 
(%)         
Japan-353 
R&D change 
(%)
1 year 3 years  
1 year 3 years 1 year
3 
years 1 year
3 
years
1
Software & Computer 
Services
11.8 14.2 10.0 12.6 10.4 -4.7 -8.4
2 Industrial Engineering 9.8 12.3 10.0 9.4 13.3 3.4 4.2
3 Automobiles & Parts 8.9 14.4 12.6 -2.6 5.1 6.4 5.3
4
Technology Hardware & 
Equipment
8.8 -2.3 1.4 14.8 9.7 -4.1 -0.5
5
Health Care Equipment & 
Services
8.3 8.7 7.6 8.5 6.2 4.9 3.9
6 Aerospace & Defence 7.0 9.5 6.1 -1.3 1.3   
7 Chemicals 6.9 8.6 3.8 7.0 8.4 0.7 0.9
8
Pharmaceuticals & 
Biotechnology
4.1 3.2 3.7 4.3 5.7 4.8 -0.1
9 Oil & Gas Producers 3.8 9.5 4.7 2.2 1.4 -4.9 9.8
10 Leisure Goods 2.9 1.7 2.5 -4.6 -2.6 2.5 2.2
11
Electronic & Electrical 
Equipment
2.5 4.4 4.2 6.1 8.2 -6.9 0.6
12 Food Producers 1.1 6.3 7.2 -12.4 1.8 0.0 1.6
13
Fixed Line 
Telecommunications
0.6 -4.6 -6.1 7.5 9.3 0.5 -1.1
14 General Industrials 0.2 5.6 4.7 7.2 10.2 -9.7 -3.2
15 Banks -4.3 -6.8 13.4     
Total 40 industries 6.2 6.3 6.6 8.2 8.0 0.4 1.2
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD
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R&D intensity by sector
Table 3.2 provides the list of industrial sectors ranked by 
worldwide R&D intensity of the main industrial sectors for 
the 2000 Scoreboard companies grouped by main world 
region. 
The following points are observed:
• Some industrial sectors increased their R&D intensity as 
R&D investment increased more than net sales in 2012, 
in particular the Technology Hardware & Equipment (8.8% 
vs. 1.9%) and the Industrial Engineering sector (9.8% vs. 
3.5%). The opposite happened for the Electronic & Electric 
Equipment sector (2.4% vs 5.5%). 
• Four sectors have an R&D intensity of more than 5.0%: 
Pharmaceuticals & Biotechnology, IT sectors (Software 
& Computer Services and Technology Hardware & 
Equipment) and Leisure Goods. The sector with the lowest 
R&D intensity is Oil & Gas Producers (0.3%). 
• Among the top 15 sectors, the R&D intensity of EU 
companies is larger than that of the US and Japan in 
6 sectors (Software & Computer Services, Technology 
Hardware & Equipment, Industrial Engineering, General 
Industrials and Automobiles & Parts and Aerospace & 
Defence) but the EU sector is much smaller than that of 
the US one for the first two of these sectors. Japanese 
companies show higher R&D intensity than the EU and the 
US in sectors such as Electronic & Electrical Equipment 
and Chemicals. The R&D intensity of US companies is 
higher than that of the EU and Japan in Pharmaceuticals 
& Biotechnology.
• As observed in previous Scoreboards, the overall lower 
average of R&D intensity of the EU companies is due to 
their large share of low R&D-intensive sectors as compared 
Table 3.2 Ranking of industrial sectors by overall R&D intensity for the EU, US and Japanese companies in 
the 2013 Scoreboard
Rank Sector Overall sector R&D intensity, %
EU-527 
sector R&D 
intensity, %
US-658
sector R&D 
intensity, %
Japan-353 
sector R&D 
intensity, %
1
Pharmaceuticals & 
Biotechnology
14.4 13.9 15.8 13.2
2
Software & Computer 
Services
9.9 12.6 11.5 4.8
3
Technology Hardware & 
Equipment
7.9 14.5 8.8 6.1
4 Leisure Goods 6.3 3.3 5.3 6.7
5 Aerospace & Defence 4.5 6.0 3.0  
6
Electronic & Electrical 
Equipment
4.3 4.8 4.3 5.2
7 Automobiles & Parts 4.2 5.1 3.7 4.3
8
Health Care Equipment & 
Services
4.1 3.6 3.9 6.9
9 Industrial Engineering 2.8 3.5 3.0 2.0
10 Chemicals 2.7 2.0 3.4 3.9
11 General Industrials 2.5 5.1 3.1 2.2
12 Banks 2.0 1.8   
13
Fixed Line 
Telecommunications
1.7 1.5 1.1 2.5
14 Food Producers 1.3 1.5 0.9 1.5
15 Oil & Gas Producers 0.3 0.3 0.3 0.2
 Total 40 industries 3.2 2.6 4.9 3.5
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD
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to a similar group of non-EU companies. Conversely, the 
high average  R&D intensity of the US companies is due 
to their considerable weight in high R&D-intensive sectors 
(see Figures 3.1 and 3.2)
Growth of net sales and profitability by industrial 
sector
Table 3.3 shows the ranking of the top 15 industrial sectors 
by overall one-year growth of net sales for the companies 
based in the EU, the US and Japan. It also includes the sector 
profitability for these regions.
The following points are observed:
• Worldwide, the Automobiles & Parts sector shows the 
highest one-year growth rate of net sales (8.8%), followed 
by Software & Computer Services (7.4%), Food Producers 
(7.3%) and Aerospace & Defence (6.4%). Regarding the 
automotive sales, it is worth noting a couple of points: 
First, the Japanese earthquake in 2011 meant that sales 
recovered strongly in 2012 as Toyota and others ramped 
production back up. Second, 2012 vehicle sales in units 
were up 5.2% but volume fell 5.9% in Europe with only 
Russia and the UK showing reasonable increases (figures 
from wardsauto.com). This means that the Scoreboard 
sales growth figures for European automotive companies 
suggest that they did well in exporting to the expanding 
markets of North America and Asia Pacific.
• Among the companies based in the EU, the highest 
growth rates of net sales are in Leisure Goods (16.3%), 
the Automobiles & Parts sector (11.3%) and Food 
Producers (10.1%). The sector showing the lowest one-
year sales growth is Technology Hardware & Equipment 
(-9.3%). Among the largest sectors in the EU, the highest 
Table 3.3 Ranking of top 15 industrial sectors by overall one-year sales growth for the EU, US and Japanese 
companies in the 2013 Scoreboard
Rank Sector
World-wide
Sales growth 1y 
(%)
EU-527 US-658 Japan-353 
Sales 
growth 
1y (%)
Profit.*
Sales 
growth 
1y (%)
Profit.*
Sales 
growth 
1y (%)
Profit.*
1 Automobiles & Parts 8.8 11.3 5.2 0.0 -3.2 11.9 5.6
2 Software & Computer Services 7.4 9.7 18.2 6.9 23.9 -0.2 2.8
3 Food Producers 7.3 10.1 10.7 3.8 10.4 1.6 3.5
4 Aerospace & Defence 6.4 8.3 7.0 6.7 9.0   
5 Electronic & Electrical Equipment 5.5 5.0 9.1 1.2 13.1 -1.3 3.2
6 Oil & Gas Producers 3.7 2.8 9.4 -3.0 16.7 2.3 1.8
7 Health Care Equipment & Services 3.5 8.7 15.4 2.1 8.5 -1.7 7.6
8 Industrial Engineering 3.5 4.1 8.4 6.4 11.6 2.6 5.0
9 Chemicals 2.2 3.0 9.9 3.7 10.8 -1.5 4.4
10 Technology Hardware & Equipment 1.9 -9.3 -1.1 6.8 14.9 -1.2 6.6
11 Pharmaceuticals & Biotechnology 1.9 2.8 19.0 -0.3 21.7 3.5 8.9
12 General Industrials 1.5 6.9 6.4 4.7 11.6 -0.2 4.2
13 Fixed Line Telecommunications 0.5 -1.1 8.7 0.7 10.1 1.8 11.5
14 Banks -1.1 -1.8 6.8     
15 Leisure Goods -1.4 16.3 21.0 -2.7 9.1 -0.5 3.6
 Total 40 industries 4.2 4.3 8.1 2.9 13.0 3.3 4.4
* Profitability:  operating profits as percentage of net sales.
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD
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profitability is shown in Pharmaceuticals & Biotechnology 
(19.0%) and Software & Computer Services (18.2%). The 
EU companies’ negative profitability of the Technology 
Hardware & Equipment sector (-1.1%) is mostly due to 
large losses incurred by Nokia, STMicroelectronics and 
Alcatel-Lucent. 
• Among the companies based in the US, the Software & 
Computer Services sector shows the highest one-year 
growth rate for sales (6.9%) followed by Technology 
Hardware & Equipment (6.8%). Sectors showing the 
lowest one-year R&D growth are Leisure Goods (-2.7%) 
and Oil & Gas Producers (-3.0%). The US-based companies 
have the highest profitability in Software & Computer 
Services (23.9%) and Pharmaceuticals & Biotechnology 
(21.7%). The US companies’ negative profitability of the 
Automobiles & Parts sector (-3.2%) to a large extent 
reflects the major losses of General Motors. The negative 
sales growth rate in Pharmaceuticals & Biotechnology 
(-0.3%) reflects patent expiries for Pfizer, BMS and Abbott.
• For Japanese companies, the highest one-year growth 
rate is shown by Automobiles & Parts (11.9%) and 
Pharmaceuticals & Biotechnology (3.5%). The poorest 
performance is shown by the Health Care Equipment & 
Services sector (-1.7%). The profitability of companies 
based in Japan is generally lower than their counterparts 
in the EU and the US, for example 8.9% in Pharmaceuticals 
& Biotechnology vs. 19.0% for the EU companies. 
Changes in indicators by region and sector groups
It is interesting to see the distribution of R&D investment 
of the Scoreboard companies across regions and sectors 
using an aggregation of the 40 industrial sectors into four 
groups of high-, medium-high-, medium-low- and low- R&D 
intensity (see Box 1.1 in chapter 1).
The worldwide and domestic distribution of the R&D 
investment by the 2000 Scoreboard companies shows clear 
differences by world region, illustrating respectively the 
weight of the region in the world and its specialisation (See 
Table 3.4): 
• Companies based in the EU specialise in medium-high 
R&D-intensive sectors (44.5% of total R&D of the EU 
companies) and contribute 34.8% of the total world R&D 
of that sector group. Two sectors, Automobiles & Parts and 
Industrial Engineering, account for almost 70% of the total 
R&D investment of the EU’s medium-high R&D intensity 
group.
• Those based in the US specialise in high R&D intensive 
sectors (73.3% of total R&D of the US companies) 
and contribute 50.3 % of the world R&D of that sector 
group. Three sectors, Pharmaceuticals & Biotechnology, 
Technology Hardware & Equipment and Software & 
Computer Services, account for almost 90% of the total 
R&D investment of the US’s high R&D intensity group.
• Japanese companies specialise in medium-high R&D 
intensive sectors (58.2%) while contributing 29.4% of 
world R&D of that sector group. Two sectors, Automobiles 
& Parts and Electronics & Electric Equipment, account for 
68.6% of Japan’s medium-high R&D intensity group.
Table 3.4 World and domestic R&D distribution of the 2000 Scoreboard companies by sector groups for the 
main regions.
Sector HighShare, %
Medium-high
Share, %
Medium-low
Share, %
Low
Share, % Total
Region world domestic world domestic world domestic world domestic domestic
EU 22.3 39.0 34.8 44.5 40.4 6.4 45.1 10.1 100
US 50.3 73.3 20.7 22.1 25.2 3.3 7.0 1.3 100
Japan 12.2 33.0 29.4 58.2 19.8 4.9 11.4 3.9 100
Other 
countries
15.2 47.0 15.2 34.4 14.7 4.1 36.5 14.5 100
Total world 100 100 100 100  
Note : Sector groups as defined in Box 4.1.
Source:   The 2013 EU Industrial R&D Investment Scoreboard.
               European Commission, JRC/DG RTD
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This chapter discusses the R&D and economic trends of 
companies based in Members States of the EU. This specific 
analysis is based on an extended sample of companies 
representing the top 1000 R&D investors in the EU, i.e. the 
527 EU companies included in the world top 2000 sample 
and 473 additional companies based in the EU.  The main 
questions addressed are firstly about the one-year changes 
in R&D and economic indicators of companies based in the 
top 10 Member States by level of R&D investment. The 
second question regards the long-term trends of company 
results, namely the rate of growth of R&D and net sales and 
profitability for companies based in the top three Member 
States of the EU. 
Key findings
• Companies based in Germany, the top R&D investor, 
continued with the good performance shown in the past 
year, increasing R&D in 2012 to well above the world 
average, at 11.6 %. On the contrary, companies based in 
the UK and France showed a poor performance, increasing 
R&D by 0.5% and 2.3% respectively.      
• Among the group of the 10 largest EU countries, those 
whose companies increased R&D above the EU average 
were Italy (18.3 %), Ireland (10.7 %), the Netherlands (7.7 
%) and Sweden (6.7 %). Companies based in three countries 
decreased R&D in 2012: Finland (-10.3 %), Denmark (-3.0 
%) and Spain (-2.1 %). These three countries have their 
total R&D dominated by that of only a few companies, e.g. 
Nokia accounting for nearly 74% of Finland’s R&D in the 
Scoreboard.
• The analysis of 10-year trends of R&D and economic 
results for companies based in Germany, the UK and France 
show the effects of the crisis in 2008-2009 and the strong 
recovery over 2010-2012 for the German companies.
Overview of the EU 1000 companies  
The composition of the sample of the EU 1000 companies 
across industrial sectors and countries is found in Annex 
3.  This sample, as well as the global 2000, shows a high 
concentration of companies by sector and country. The 6 
largest sectors in terms of R&D account for 50% of the 
companies. These sectors and the countries accounting for 
at least 15% of the companies each are:
4 The top 1000 R&D investors in 
the EU
Software & Computer 
Services
113 UK 47, France 21, Germany 19
Pharmaceuticals & 
Biotechnology
112 UK 30,  France 18
Industrial Engineering 112 Germany 42
Electronic & Electrical 
Equipment
73
Germany 16, UK 15, 
France 12
Automobiles & Parts 50
Germany 20, UK 11, 
France 6
Technology Hardware 
& Equipment
46
UK 11, Germany 7, 
Sweden 7
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A look at the lower reaches of the EU top 1000 
companies
Table 4.1 below compares the sector composition of 
the upper (EU companies which belong to the World top 
2000 companies) and lower reaches of the top 1000 EU 
Scoreboard companies across the 6 largest sectors in terms 
of R&D investments.
A closer look at the lower reaches of the EU Scoreboard 
companies (i.e. EU top 1000 companies which do not belong 
to the World top 2000 companies) provides interesting 
insights regarding future potential leading EU companies. 
The general picture reveals that:
• More than 55% of these companies in the sectors of 
Electronic and Electrical Equipment, Pharmaceuticals & 
Biotechnologies and Software & Computer services have 
Table 4.1 Distribution of top and bottom EU companies in selected sectors
Selected sectors Top group of EU 1000 (number of firms)
Bottom group of EU 1000 
(number of firms)
Pharmaceuticals & Biotechnology 59 (23%) 52 (21%)
Software & Computer Services 37 (14%) 74 (30%)
Technology Hardware & Equipment 29 (11%) 17 (7%)
Electronic & Electrical Equipment 38 (15%) 38 (16%)
Automobiles & Parts 36 (14%) 14 (6%)
Industrial Engineering 62 (24%) 50 (20%)
Total 261 245
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
Figure 4.1 Main country and sector distribution of the EU 1000 companies
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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a higher R&D intensity than the average of the 527 EU 
companies. 
• The share of companies with a higher R&D intensity than 
that of the top European companies exceeds 40% in the 
sectors of Industrial Engineering and Technology Hardware 
& Equipment. 
• This proportion drops to about 20% in the sector 
of Automobiles & Parts since almost all the vehicle 
manufacturers are in the top 527. 
The country distribution of the lower reach reveals that 
four countries account for about 75% of the total number 
of companies within the six selected sectors. The UK and 
Germany represent respectively 30% and 20% of the 
companies in these sectors while the proportions are about 
15% and 10% for France and Sweden. Figure 4.1 below gives 
a more detailed view of the distribution of companies in the 
lower and upper reaches of the top 1000 EU for these four 
countries.
With respect to the sector distribution of R&D intensity by 
country, the following main points are observed: 
• In the Automobile and Parts sector, only UK companies 
display a higher R&D intensity than that of the average of 
the top 527 EU companies. 
• All the Swedish companies operating in the Technology 
Hardware and Equipment sector show higher performances, 
as compared to the upper reach average. 
• In the sector of Electronic and Electrical Equipment, French 
and German companies record a higher R&D intensity than 
the average of the top 527 EU companies.
• In the Industrial Engineering sector, Germany clearly 
outperforms as two third of its companies display an R&D 
intensity higher than the average of the upper reach, while 
the relative performance of the UK is not outstanding, as 
only one fourth of its companies exceed this average. 
• Despite a lower number of companies, Germany also 
performs relatively better than France and the UK also in 
the Pharmaceuticals and Biotechnology sector. Indeed, all 
German companies have an above-average R&D intensity 
(compared to that of the top 527 EU companies), while the 
same holds true for about 60% and 50% of French and UK 
companies, respectively. 
• Swedish and UK companies in the Software and Computer 
Services sector show high performances as more than 80% 
display a higher R&D intensity than the upper reach average. 
In Germany, this proportion drops to about 60% while only 
half of the French companies are above this average. 
Although these first observations provide relevant insights, 
the identification of future potential EU leading or top R&D 
companies deserves further detailed analyses at both the 
sector and company levels.
Trends of companies in the top 10 Member States of 
the EU
The companies based in the top 10 Member States account 
for 97.3 % of the total R&D of the 1000 EU companies (see 
table 4.2). 
Among the group of the three top R&D investing countries 
(accounting for 67.5 % of the total R&D), companies based 
in Germany, the top R&D investor, had a double-digit average 
R&D growth, at 11.6 % compared with 9.5% increase in 
the previous year. Companies based in the UK and France 
increased R&D by 0.5% and 2.3 respectively, well below the 
world’s average (6.2%). In terms of net sales, German and 
French companies grew by 6.7% and 6.8%, above the world’s 
4.2% increase. On the contrary, UK companies had reduced 
sales by 1.2%.  The global sales growth of the automotive 
market contributed to the sales growth of German companies, 
showing, in particular, success in exporting to the growing 
markets of North America and Asia Pacific rather than being 
limited to the shrinking European market of 2012.  
Apart from the group of the three top countries, companies 
increased R&D above the EU average in Italy (18.3 %), Ireland 
(10.7 %), the Netherlands (7.7 %) and Sweden (6.7 %). Among 
these companies, those based in Italy also had a double-
digit growth in net sales (11.7%). Companies based in three 
countries decreased R&D in 2012: Finland (-10.3 %), Denmark 
(-3.0 %) and Spain (-2.1 %). Among these companies, those 
from Finland showed also a decrease of net sales (-1.3%).
It is important to remember that in many countries, the 
aggregate country indicators depend to a large extent on the 
figures of a very few firms. This is due, either to the country’s 
small number of companies in the Scoreboard or to the 
concentration of R&D in a few large firms. For example:
• The R&D growth of Fiat (51.5%), accounting for more than 
36 % of the R&D of companies based in Italy, contributed 
a significant part of the R&D growth of that country. Fiat’s 
R&D growth was increased by its acquisition of Chrysler. 
• Three companies from the Automobiles & Parts sector, 
accounting for 32% of the R&D of companies based in 
Germany, contributed a large part of the country’s R&D 
growth: Volkswagen (32.1 %), Robert Bosch (16.1 %) and 
BMW (17.2 %). Volkswagen’s R&D growth was increased by 
its acquisition of Porsche and Man.
• Similar cases occur in Finland where Nokia’s R&D investment 
accounts for almost 74% of the total R&D by Finnish 
companies and in Ireland with Seagate Technology (12.6 
%), Covidien (12.5%) and Accenture (11.2%), accounting for 
60% of the R&D of companies based in Ireland. 
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Long-term performance of companies based in the 3 
top EU Member States
The annual growth rates of R&D investment and net sales 
and profitability of companies based in Germany, France and 
the UK is provided respectively in figures 4.2, 4.3 and 4.4 
for the period 2004-2012. These figures are based on our 
history database comprising R&D and economic indicators 
over the whole 2004-2012 period from the EU 1000 dataset, 
including 135 from Germany, 81 from France and 122 from 
the UK. 
The trends observed in these figures show the behaviour 
of these companies including the effects of the crisis that 
began in 2008. The following points are observed:   
• Companies based in Germany seem to have recovered the 
levels of growth of R&D investment and net sales prior to 
the crisis.   
• Since 2012, companies based in France have recovered a 
level of net sales similar to that of the period preceding 
the crisis; however, in terms of R&D the recovery observed 
in 2010-2011 was interrupted in 2012. 
• For the companies based in the UK, the strong recovery 
shown in 2010-2011 was broken up in 2012 for net 
sales growth but R&D growth resumed from the low level 
reached in 2011. 
• Sector composition of the country samples to a large extent 
reflects the differences observed in terms of profitability.
Table 4.2  R&D trends of companies based in the top 10 EU Member States
Country No. of companies R&D share 
within EU
R&D one year
growth, %
Net sales
One year growth, 
%
Germany 224 35.1 11.6 6.7
France 124 17.5 2.3 6.8
UK 252 14.8 0.5 -1.2
The Netherlands 55 8.3 7.0 4.1
Sweden 88 6.1 6.7 0.5
Italy 46 5.6 18.3 11.7
Finland 45 3.5 -10.3 -1.3
Spain 22 2.5 -2.1 3.9
Denmark 37 2.2 -3.0 10.3
Ireland 16 1.8 10.3 0.8
Total EU-10 909 97.3 6.1 4.3
For the sample of 1000 EU companies.
Source:  The 2013 EU Industrial R&D Investment Scoreboard. 
European Commission, JRC/DG RTD.
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Figure 4.2 Annual R&D and net sales growth and profitability* by the German companies
Note: For 135 German  out of the EU1000 companies with data for the whole period
* Profitability expressed as companies’ profits as percentage of net sales 
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
Figure 4.3 Annual R&D and net sales growth and profitability* by the French companies
Note: For 81 French out of the EU1000  companies with data for the whole period
* Profitability expressed as companies’ profits as percentage of net sales  
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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R&D intensity trends by companies based in selected 
Member States
In 2012, for the second consecutive year, the average R&D 
intensity of the EU-1000 companies increased slightly 
because of the higher increase of R&D investments compared 
to that of net sales, 6.1% vs. 4.3% (see Figure 4.5). 
It is important to remember that a few large but low R&D 
intensity companies have a big effect on some country 
average R&D intensities. One example is Shell and BP for the 
UK. In the 2012, these companies contributed about 42% of 
the UK’s Scoreboard company sales, so practically doubling 
the average R&D intensity of UK companies had they been 
left out.
Figure 4.4 Annual R&D and net sales growth and profitability* by the UK companies
Note: For 122 UK out of the EU1000 companies with data for the whole period.
* Profitability expressed as companies’ profits as percentage of net sales
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
Figure 4.5 Trends in R&D intensities for EU Scoreboard companies in selected Member States
Note: For the EU1000 companies in each of the ten Scoreboards 2004-2013
Source:  The 2013 EU Industrial R&D Investment Scoreboard 
European Commission, JRC/DG RTD.
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This chapter reviews the healthcare sector and focuses 
on therapeutic biotechnology and pharmaceuticals and 
analyses the role of the Scoreboard companies operating in 
this industry.
Key findings
• The global biotech market is expected to rise 54% from 
2012 to 2017 with 60% being therapeutic biotech. This 
demonstrates the growing importance of biotech in 
replenishing the new drug pipelines of pharmaceutical 
companies.
• The demand for new medicines is growing due to rising 
and ageing populations and the increasing wealth of 
emerging nations. But pharmaceutical companies over 
the last decade have faced the ‘patent cliff’ of expiring 
blockbuster patents, increased regulation and decreasing 
productivity of their conventional R&D. At the same time 
technological advances in therapeutic biotech have opened 
up new opportunities.
• The big pharmaceutical companies have responded to 
these challenges first by pharmaceutical acquisitions 
to reduce costs and then by biotech acquisitions and 
collaborations to enhance their new drug pipelines. The 
Scoreboard allows us to track these changes at company 
level from 2005 to 2012.
• The Scoreboard shows that the therapeutic biotech sector 
is now dominated by the US which has all the top five 
biotech companies and eight of the top ten. But there are 
a number of examples of EU companies which show both 
high performance and the ability to grow to a sustainable 
size through well-chosen collaborations.
5.1 Introduction and scope
This chapter is concerned with the development of R&D-
led healthcare companies over the last decade from 2005 
to 2013. There are two main ICB sectors contributing to 
healthcare R&D – pharmaceuticals & biotechnology and 
health. These two sectors account for just over 20% of the 
total R&D in the world top 2000 companies but constitute 
two of the eight highest R&D intensity sectors (intensity over 
4%). Total health sector R&D is only about 12% of the R&D 
in pharmaceuticals & biotechnology
We are going to focus on R&D–led healthcare companies 
so we will exclude biotech companies in non-healthcare 
applications which account for about 40% of global biotech 
sales. The reason is that therapeutic biotechnology dominates 
the biotech sector in the Scoreboard and is accounting for a 
larger and larger proportion of the new drugs launched by 
pharmaceutical companies. The health sector will be covered 
only briefly for reasons of space and because the biotech/
pharma story is so significant. The area of diagnostics, 
however, will be mentioned towards the end of this chapter 
because of its growing importance in the future of biotech/
pharma. Roche is a leader in diagnostics which accounts for 
about one fifth of its revenue.
The profile of the global biotechnology sector and the split 
between sub-sectors according to Marketwatch’s 2013 
survey is:
• The global biotech market is forecast to rise from $304bn 
in 2012 to $468.1bn in 2017, an increase of 54%
• The market segmentation in 2012 was 60% medical/
healthcare, 13.8% food & agriculture, 7% environment 
& industrial processing and 19.2% services (including 
technology services)
• The segmentation by region was the Americas 45.4%, 
Europe 26.1%, Asia Pacific 26.1%, the Middle East & Africa 
2.4%. There are significant differences between regions 
with the US having 61.6% in healthcare, Europe 68.1% but 
Japan only 35.9%
We will be focusing on healthcare in this chapter with 
particular reference to the growing importance of biotech 
to pharmaceutical companies with up to 50% of new drugs 
expected to come from biotech by 2018 compared to just 
12% in 2004 (data from EvaluatePharma’s 2013 report). 
5 Sector focus: Health & 
biotechnology 2005-13
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But before discussing the details and the companies involved 
we need to describe the main features of the business 
environment in which these major changes are occurring.
5.2 The business environment 
for healthcare
There are four major trends occurring in healthcare which 
are driving changes in the whole business environment. 
These are:
• The increasing demand for healthcare due to ageing 
populations and the growing wealth of developing 
countries. The proportion of the world population over 60 
will more than double from 10% in 2000 to 21% in 2050. 
And in China it will more than triple from 10% to 32.8% 
by 2050. The combination of rising and ageing populations 
and increasing GDP means, according to Ernst & Young, 
that up to 90% of the growth of the pharmaceutical 
industry will be provided by emerging markets by 2020.
• Technological innovations range from biotech drugs or 
software-driven MRI scanners and radiotherapy systems 
to micromechanical devices like drug-eluting stents and 
robotic-assisted surgery. And coming over the horizon is 
personalised medicine with drugs tailored to a patient’s 
genetic makeup – this combines diagnostics with tailored 
drugs. These changes have already reduced death rates 
from heart disease and cancer. Now biotech innovations 
are enabling patients with serious diseases like HIV and 
Hepatitis C to be treated and there are new biotech 
drugs being developed to treat more cancers and serious 
conditions like rheumatoid arthritis.
• Increased regulation and demands for proof of increased 
efficacy for new drugs have occurred as a response to 
safety concerns and rising costs. The FDA (US Food & 
Drug Administration) tightened up its approval and other 
procedures in 2007 following cases such as the withdrawal 
of Merck’s painkiller Vioxx in 2004 after it was shown that 
the drug increased the risk of a heart attack. And Pfizer 
was fined $2.3bn in 2009 for off-label marketing of its 
arthritis drug. There has also been a move to introduce 
cost-effectiveness analysis (CEA), particularly in the single-
payer health systems of Europe. NICE (National Institute of 
Clinical Excellence) in the UK was an early example (1999). 
CEA supports the notion that higher prices can be charged 
for more efficacious drugs which should encourage R&D.
• The business response of the big pharmaceutical 
companies to the challenges of patent expiries, increased 
regulation, reduced R&D productivity (because of the 
increasing difficulties of finding new blockbuster small 
molecule drugs) and to rapid biotech advances has 
been via increased M&A and collaborations with smaller 
biotechs. 
We will expand on the last of these trends to set the scene 
for the discussion in the next section of the trends in R&D, 
sales and profits of both biotech and pharma companies in 
the Scoreboard from 2005 to 2012 and how these reflect 
the changes in the healthcare landscape and illustrate the 
way in which different companies have responded to them.
While global pharmaceutical companies have benefited 
from the increasing demand for new and better drugs, they 
have also faced a series of challenges over the last decade 
including increased regulation and CEA. The two most serious 
ones have probably been the expiry of patents on a whole 
series of blockbuster drugs and the decreasing productivity 
of R&D as new blockbusters based on conventional small 
molecule drugs became harder to discover. 
Once a drug loses patent protection generics siphon off up 
to 90% of its sales. The large number of patent expiries 
occurring between 2010 and 2015 has been termed the 
‘patent cliff’ and all the major pharmaceutical companies 
have been affected by it. The ‘cliff’ extends from 2010 to 
2016. The scale and importance of the cliff is demonstrated 
by Pfizer which, just between 2010 and 2012, lost patent 
protection on drugs like Lipitor, Protonix and Geodon which 
made up 42% of its revenue. Lipitor was the world’s top 
selling drug with peak revenues of $12.9bn in 2006. And 
Chemistry World reported last July that Eli Lilly is freezing 
the pay of its employees in 2014 to save money ahead of 
the expiry of two key patents which will cause revenue to 
fall by 20%.
Big pharma companies have responded to these massive 
losses in sales in three main ways. Cost cutting, M&As 
between pharmaceutical companies, more focused R&D 
and refilling of pipelines using biotech drugs from biotech 
companies (through acquisition and collaboration). Cost 
cutting has involved all the functions of these companies. 
R&D has been reduced in some, such as Pfizer which closed 
its UK research laboratories in Kent which had a long record 
of innovation including discovering the drug Viagra. Other 
companies used mergers and acquisitions to enable them 
to reduce the R&D of the newly combined companies. 
In manufacturing there has been a trend to use outside 
contract manufacturing companies with the closure of in-
house manufacturing plants. And big savings have been 
made in marketing and selling expenses by co-marketing 
and downsizing sales with ZS Associates estimating that the 
number of US pharmaceutical sales representatives would 
shrink by 26% from 2007 to 2012.
In the next section we use the Scoreboard to explore two 
issues in more detail. These are the M&A deals between 
2004 and 2013 and the development of new drugs using 
biotechnology. One of the first pharmaceutical companies 
to understand the importance of biotechnology was Roche 
which, in 1990, took a majority stake in Genentech, the first 
ever therapeutic biotech company which was formed in 
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1976 in the US. It now owns 100% of Genentech which is 
responsible for many of Roche’s pipeline drugs.
5.3 A multi-year Scoreboard 
survey of the biotech/pharma 
sector 
In this section we use the run of R&D Scoreboards from 
2005 to 2013 to track the R&D and business performance of 
biotech and pharma companies. We will first give an overview 
of the whole company set, examine the characteristics of 
the larger companies and then look at the way some typical 
companies have developed over the decade and faced the 
challenges described in section 2. We will conclude by looking 
at some mainly smaller biotech companies and examining 
how they have grown and the nature of collaborations they 
have formed with large pharmaceutical companies.
5.3.1 Pharmaceutical & biotechnology companies in the 
2013 Scoreboard
There are 214 companies in total in the Pharmaceuticals 
and Biotechnology sector out of the world top 2000 included 
in this year’s Scoreboard. This 10.7% of the companies 
accounts for 18% of the R&D in the Scoreboard and the 
sector has by far the largest R&D intensity (14.4%). There 
are five companies from the sector in the overall top ten 
by R&D in the Scoreboard, two from Switzerland and three 
from the US. 
The 214 companies have been assigned either to biotech 
or pharma. There is inevitably a grey area between the two 
so not all the assignments may be the same as those made 
in stock market classifications such as the Nasdaq sectors. 
These assignments give us 89 companies in biotech and 125 
in pharma. Table 5.1 gives an overview of the two sectors and 
the contributions of each world region. The US has 74.2% of 
the biotech companies and 86.0% of the R&D. The EU has 
20.2% of the companies and 9.9% of the R&D so the EU 
companies are on average much smaller. In pharmaceuticals 
the US has 26.4% of the companies but 38.4% of the R&D 
whereas the EU has 32.0% of the companies but 30.0% of 
the R&D. 
Table 5.1 Overview of the Scoreboard companies in the Pharmaceuticals & Biotechnology sector      
 EU US Others World 
Biotechnology     
No. companies 18 66 5 89
Employees 18,832 67,986 17,269 104,087
R&D investment, € m 1,190 10,300 445 12,000
Net Sales, € m 5,450 40,100 4,890 50,400
R&D intensity (*) 17% 25% 9% 23%
Profitability (*) 13% 28% 24% 26%
Pharmaceuticals 
No. companies 40 33 52 125
Employees 596,006 589,294 529,622 1,714,922
R&D investment, € m 26,500 33,700 27,500 87,700
Net Sales, € m 192,000 225,000 208,000 624,000
R&D intensity (*) 14% 15% 13% 14%
Profitability (*) 19% 23% 16% 19%
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Given the large number of companies we will focus on the 
top 25 in each category and use the run of Scoreboards to 
understand some of the big changes that have occurred 
over the last eight years in response to the challenges we 
outlined in section 5.2. 
5.3.2 Sector trends 2005-2012
R&D in both the biotech and pharma sub-sectors is 
dominated by the larger companies. For example, the top 10 
biotechs account for 63% of the R&D of all 89 companies 
while the top 10 pharmas account for 58% of the R&D of all 
125 companies. The characteristics of the top 30 companies 
from each subsector are:
• Biotechnology: Top 30 companies by R&D with R&D 
ranging from €62m (and sales €0.8m) to R&D of €2.3bn 
(and sales €12.6bn). A total of 25 of these companies are 
from the US, 4 from the EU and one from Australia. All are 
in therapeutic biotech except two of those from the EU 
– Novozymes in industrial biotech (enzymes) and Qiagen 
(sample and assay technologies). 
• Pharmaceuticals: Top 30 companies by R&D with R&D 
ranging from €0.33bn (and sales €2bn) to R&D of €7bn 
(and sales €37.8bn). A total of 9 of these are from the US, 
13 from Europe (10 from the EU and 3 from Switzerland), 
7 from Japan and one from Israel.
The relative numbers of EU and US companies in the two 
sectors show that the US dominates the world in larger 
therapeutic biotech companies and that Japan lags behind 
the EU in both areas. 
Now the companies in the top ranks have changed markedly 
from 2005 to 2013. To understand this we will discuss 
M&As in the pharma sector, the rise of biotechnology and 
the modes of collaboration between big pharma companies 
and smaller, growing companies that are mainly biotechs.
M&As between large pharmaceutical and biotech 
companies
Some of the trends in the pharmaceutical sector can be seen 
from a comparison of the top 25 in 2005 and 2012. Of the 
top 25 pharmaceutical companies by R&D in 2005, only 17 
made it into the top 25 of 2012. This was because five of 
them were acquired while the R&D of the other three did 
not increase enough to reach the top 25 of 2012. Wyeth 
was acquired by Pfizer for €45.5bn, Schering by Bayer for 
€17bn, Schering-Plough by Merck (US) for €25.5bn, Altana 
by Nycomed for €4.6bn and Schwarz Pharma by UCB for 
€3.8bn. Pfizer had already acquired Warner-Lambert in 
2000 and Pharmacia in 2003.
5  S e c t o r  f o c u s :  H e a l t h  &  b i o t e c h n o l o g y  2 0 0 5 - 1 3
49
Table 5.2 Top 25 Pharmaceutical  R&D investors in 2005 seven years later
Company Country R&D2012/2005 
World 
Rank 
2005
World Rank 2012
Pfizer USA 91% 2 10
Johnson & Johnson USA 109% 7 9
GlaxoSmithKline UK 93% 10 20
Novartis Switzerland 169% 13 7
Sanofi-Aventis France 121% 16 15
Roche Switzerland 191% 19 6
Merck US USA 184% 21 8
AstraZeneca UK 118% 28 33
Eli Lilly USA 156% 32 26
Wyeth USA - 36 Acquired by Pfizer - Deal value: 45,536,102 th 
EUR
Bristol-Myers Squibb USA 122% 37 40
Bayer Germany 169% 46 36
Schering-Plough USA - 56 Merged with Merck US - Deal value: 
25,487,802 th EUR
Abbott Laboratories USA 212% 58 35
Boehringer Ingelheim Germany 206% 61 42
Takeda 
Pharmaceutical Japan 280% 74 41
Schering Germany - 77 Acquired by Bayer AG - Deal value: 
17,000,000 th EUR
Merck DE Germany 212% 97 73
Novo Nordisk Denmark 205% 101 79
Eisai Japan 187% 121 108
UCB Belgium 153% 133 146
ALTANA Germany - 146 Acquired by Nycomed - Deal value: 4,600,000 
th EUR
Yamanouchi 
Pharmaceutical Japan - 156
70 (now Astellas Pharma Inc., they merged 
with Fujisawa Pharmaceutical Co., Ltd)
Mitsubishi Pharma Japan - 169 Now controlled by Mitsubishi Chemical 
Holdings Co.
Forest Laboratories USA 194% 177 162
Allergan USA 226% 185 149
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Table 5.3 Top 25 Biotechnology specialised R&D investors in 2005 seven years later
Company Country R&D2012/2005 
World 
Rank 
2005
World Rank 2012
Amgen USA 131% 45 47
Biogen Idec USA 160% 110 111
Serono Switzerland 129 Acquired by Merck DE  - Deal value: 4,737,838 
th EUR
Genzyme USA 158 Acquired by  Sanofi-Aventis - Deal value: 
14,055,061 th EUR
Chiron USA 173 Acquired by Novartis AG - Deal value:  
4,304,064 th EUR
MedImmune USA 190 Acquired by  AstraZeneca - Deal value:  
11,387,012 th EUR
Applera USA 220 Acquired by Invitrogen (now Life Technologies 
Corporation)
Millennium 
Pharmaceuticals USA 230
Acquired by Takeda America Holdings - Deal 
value:  5,675,120 th EUR
Kyowa Hakko Kogyo Japan 255 Now controlled by Kirin Holdings Co. Ltd.
Gilead Sciences USA 567% 259 82
Human Genome 
Sciences USA 328
Acquired by  GlaxoSmithKline - Deal value: 
2,463,689 th EUR
Protein Design Labs USA 383 No more in Scoreboard
Merial UK 417 Acquired by  Sanofi-Avensis  - Deal value:  
2,713,329 th EUR
Celgene USA 951% 421 88
Medarex USA 451 Acquired by Bristol-Myers Squibb - Deal value: 
1,674,610 th EUR
Theravance USA 83% 482 793
OSI Pharmaceuticals USA 484 Acquired by  Astellas Pharma  - Deal value:  
3,343,026 th EUR
Novozymes Denmark 182% 490 425
Abgenix USA 507 Acquired by Amgen.  - Deal value: 2,187,840 
th EUR
CV Therapeutics USA 540 Acquired by Gilead Sciences - Deal value:  
1,062,355 th EUR
Vertex 
Pharmaceuticals USA 623% 546 178
CSL Australia 309% 557 330
NPS Pharmaceuticals USA 81% 567 925
Regeneron 
Pharmaceuticals USA 114% 571 720
Invitrogen USA 589
346 (now Life Technologies Corporation, under 
acquisition by Thermo Fisher Scientific Inc. 
HERMO FISHER SCIENTIFIC INC. - Health Care 
Equipment & Services)
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Despite this acquisition activity, there was only a modest 
increase in R&D from 2005 to 2012 for many of the 
large pharmaceutical companies. Pfizer’s R&D actually 
decreased over these eight years while that of AstraZeneca, 
GlaxoSmithKline and Sanofi increased by less than 25%.
The pace of change was even faster in biotech. Of the top 
25 biotechs of 2005 shown in the Scoreboard, only eight 
survived to 2012 (one under a new name) and two of them 
were not therapeutic biotechs (Novozymes and Qiagen). The 
fate of the other 17 is summarised below:
- Ten biotechs were acquired by pharmaceutical companies 
(three by Sanofi, two by AstraZeneca and one each by 
GSK, Johnson & Johnson, Merck, Novartis and Takeda) 
- One was acquired by another biotech (Agennix)        
- Six did not make the 2013 Scoreboard (one being a 
demerger)
We should also mention that, in 2009, Roche acquired 
full ownership of Genentech for $46.8bn (it already had 
a majority shareholding). The increases in R&D amongst 
profitable biotechs were also very large. There are 14 biotechs 
appearing in the 2013 Scoreboard which both tripled R&D 
from 2005 to 2012 and had a positive profitability of at 
least 4%. These are shown in table 5.4.
Table 5.4 shows key data for Gilead Sciences, Celgene, 
Life Technologies, Illumina, United Therapeutics, Alkermes, 
Emergent Biosolutions, Viropharma, BTG, Acorda Therapeutics, 
Genus, Genomic Health, Spectrum Pharmaceuticals and 
Luminex. 
The first six of these are large biotechs since they feature in 
the top 14 biotechs by R&D in this year’s Scoreboard with 
Gilead Sciences and Celgene in second and third places. 
Amgen remains at #1 as in 2005 with Biogen Idec as #4 (#2 
in 2005). Of the 14 biotechs, eleven are from the US, two 
from the UK and one from Ireland. 
The message of this chapter is that large pharmaceutical 
companies have adopted two strategies in the last decade to 
overcome the challenges outlined in section 2. The first was 
the acquisition of other pharmaceutical companies, primarily 
to reduce costs. The second has been the bolstering of their 
pipelines through the acquisition of biotech companies or 
collaborations with them.  We now look at the modes of 
collaboration between the two.
5.3.3 Collaboration between biotech and pharma compa-
nies
The biotechnology industry was started in 1976 with the 
foundation of Genentech which now employs some 12,500 
Table 5.4 Top 14 high performance biotech companies
Company Bio Rank
SB
Rank Country
R&D 
2012
(mil €)
R&D
intensity
2012
R&D
growth
Profitability
2012
Empl.
2012
GILEAD SCIENCES INC 2 82 US 1334 19% 504% 43% 5000
CELGENE CORP 3 88 US 1206 29% 914% 35% 4700
LIFE TECHNOLOGIES CORPORATION 7 346 US 259 9% 250% 19% 10000
ILLUMINA INC 11 460 US 175 20% 692% 22% 2400
UNITED THERAPEUTICS CORP 13 572 US 131 19% 381% 46% 623
ALKERMES PLC 16 702 IE 101 23% 3322% 14% 1230
EMERGENT BIOSOLUTIONS INC. 21 783 US 91 43% 554% 11% 877
VIROPHARMA  INC 38 1154 US 51 16% 538% 8% 410
BTG PLC 39 1185 UK 49 18% 383% 9% 569
ACORDA THERAPEUTICS , INC. 50 1362 US 41 18% 318% 8% 378
GENUS PLC 58 1486 UK 36 9% 394% 16% 2189
GENOMIC HEALTH, INC. 60 1501 US 36 20% 422% 4% 612
SPECTRUM  PHARMACEUTICALS,  INC. 65 1601 US 32 16% 216% 31% 193
LUMINEX CORP 70 1646 US 31 20% 628% 11% 709
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people and, since 2009, is 100% owned by Roche, an 
example of acquisition as an extreme form of collaboration. 
We have seen above how eleven of the top 25 biotechs in 
2005 were acquired, ten by pharmaceutical companies. 
Acquisitions of this type will undoubtedly continue but other 
types of collaboration are important for small biotechs that 
aim to grow fast but also remain independent. This type 
of collaboration is particularly important for smaller EU 
biotechs which need to grow larger to compete effectively 
with the many larger US ones. 
We will illustrate four different modes of collaboration with 
examples of biotech companies that are growing in these 
four ways. The data is mainly taken from the companies’ 
own websites.
• The first is Abcam, a biotech which illustrates the use 
of marketing collaborations used to expand its internet 
sales. It is a £122m sales Cambridge company that 
supplies antibodies and proteins to therapeutic and 
other biotech researchers all over the world through its 
innovative website which offers 122,000 products. It 
develops and makes only one third of its products with 
the other two-thirds sourced through collaborations. It 
provides comprehensive technical data sheets and quality 
control for these products which are all marketed through 
its website. Its growth has been mainly organic but with 
related acquisitions. Abcam had a September 2013 cash 
pile of over £38m with no debt.
• The second is MorphoSys, a biotech which has a pipeline 
of 81 potential drugs based on antibodies with 21 of 
these already in clinical trials. It is collaborating with 
several pharmaceutical companies on pipeline drugs 
and derives income from these through licence fees and 
milestone payments and will gain royalty streams when 
new partnered drugs are launched. Partners include Bayer, 
GSK, Johnson & Johnson, Novartis, Pfizer and Roche. It also 
funds development of certain proprietary drugs out of its 
own cash resources so that it can agree more lucrative 
partnerships for these at a later stage (clinical Phase II 
or III). It has just signed deals with GSK and Celgene for 
its two most advanced drugs. Even before these deals 
MorphoSys had a cash pile of €166m.
• The third is Oxford Nanopore which is developing novel DNA 
and RNA sequencing instruments one of which will sell for 
less than $1,000. It is a private company valued at £328m 
in June 2013 and was spun out of Oxford University by IP 
Group, a university research commercialisation company. 
Oxford Nanopore has just raised another £40m of funds for 
further growth. University commercialisation companies 
such as IP Group, Fusion IP and Imperial Innovations are 
helping to spin out new companies from university R&D in 
biotech and many other R&D-intensive sectors and then 
manage their growth to a viable size at which they can 
be listed.
• The fourth is Regeneron Pharmaceuticals, a US biotech 
specialising in antibody-derived drugs that illustrates 
collaborations with EU pharmaceutical companies. It has 
its first blockbuster drug on the market – Eylea – and has 
at least three more potential blockbusters in its pipeline. It 
collaborates with Bayer on Eylea with Bayer marketing the 
drug outside the US and Regeneron retaining full US rights. 
Regeneron is also collaborating with Sanofi on the joint 
development of other drugs for diseases such as asthma 
and rheumatoid arthritis. Sanofi has a 16% shareholding 
in Regeneron and can increase this to 30% under their 
existing agreement.
These four examples illustrate the different ways in which 
smaller biotechs can grow to a size where they can be self-
sustaining through generating enough cash to fund the 
development of a strong pipeline and arrange beneficial 
terms for marketing their successful drugs or devices. 
Accumulating an adequate cash pile is an important step in 
this process.
5.4 The prospects for 
therapeutic biotech companies
It is clear from the previous sections that biotechnology is 
of increasing importance and is likely to be generating over 
50% of new drugs by 2018. The US dominates therapeutic 
biotechnology, the largest segment of biotechnology. It is 
home to all five of the top biotechs with R&D over €500m and 
to nine of the top ten. European and other pharmaceutical 
companies have realised the importance of biotech as the 
likely source of the majority of new drugs in the future. They 
have therefore acquired biotech companies and collaborated 
with them in various ways.
However, Europe has a proud record of scientific discovery 
in biotech including such milestones as the structure of DNA 
and the discovery of antibodies. Europe would benefit from 
having some larger and independent biotech companies to 
build up its base of skills and commercial expertise in this 
important sector to gain full commercial benefits from its 
fundamental R&D. This chapter illustrates some of the ways 
in which this can be done ranging from university spin-out 
companies growing under the umbrella of commercialisation 
companies to the development of a well-stocked biotech 
pipeline using a combination of early and late stage 
partnerships with pharmaceutical companies.
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This chapter looks at the foreign direct investments (FDIs) of 
Scoreboard companies as a proxy of their internationalization 
strategies. 
FDI is defined as an investment made to acquire lasting 
interest in enterprises operating outside of the economy of 
the investor. The UN defines control in this case as owning 
10% or more of the ordinary shares or voting power of an 
incorporated firm or its equivalent for an unincorporated firm. 
Additional to having an equity capital or reinvested earnings 
in an enterprise, there are other ways in which foreign 
investors may acquire an effective voice in the management 
of an enterprise. These include franchising, subcontracting, 
management contracts, turnkey arrangements12, leasing, 
licensing and production-sharing. 
There are two types of FDIs used for market entry purposes: 
greenfield FDIs and mergers and acquisitions (M&As).
Although greenfield FDI projects account for a much smaller 
share in the total value of FDI, the number of greenfield 
projects greatly surpasses the number of M&A projects 
(World Investment Report, UNCTAD, 2012). 
Greenfield Foreign Direct Investments consist in the 
expansion of existing facilities or a direct investment in 
new facilities (in an area where no previous facilities exist). 
Greenfield FDIs are the primary objective of a host nation’s 
promotional efforts, as they create new production capacity 
and jobs, transfer technology and know-how, and can lead 
to linkages to the global marketplace. Investing companies, 
on the other hand, have aims such as lowering costs, 
avoiding tariff barriers, using local skills and incentives and 
understanding the specific needs of local markets.
12 A turnkey contract is a business arrangement in which a project 
is delivered in a completed state. Rather than contracting with an 
owner to develop a project in stages, the developer is hired to finish 
the entire project without owner input.
Matching the first 1500 Scoreboard companies13 with data on 
greenfield FDIs14, the objective is to show how the top world 
R&D spenders are locating and re-organizing their industrial 
activities (e.g., manufacturing, research, development 
and testing) around the world and across sectors through 
outflows of FDIs. 
Key Findings
• The EU plays a major role in the international scenario 
both as the main source and destination of knowledge 
intensive FDIs.  22% of the total number of FDIs in R&D 
is destined to the EU, while the US receives only 8 % of 
projects in R&D. 
• Six out of the ten countries with the highest number of 
international projects are European. 
• The EU attracts more technological intensive projects 
than resource-saving investments compared to the other 
economies. 
• FDIs in R&D are concentrated mainly in the three sectors 
of Technology Hardware and Equipment, Automobiles & 
Parts and Pharmaceuticals & Biotechnology.
Overview of Scoreboard Greenfield FDIs 
The total number of greenfield FDI projects undertaken 
during the period 2003-2012 by the world top 1500 R&D 
investors is 27,208 for a total capital expenditure of 2.03 
trillion Euros.
For the purpose of the analysis, intra-European FDIs and 
intra-state US investments are excluded.
13  Sample corresponding to the 2012 EU Industrial R&D Investment 
Scoreboard edition.
14 Greenfield investment data is derived from the © 2013 fDi 
Markets database (a service from the Financial Times Limited 
2013), which accounts for more than 110,000 greenfield 
investment projects around the world for the period 2003-2011. 
Information on the greenfield FDI project is derived from different 
media sources and can be interpreted as a commitment to invest 
validated with company sources.
6 Company foreign direct investments
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The breakdown of FDIs by activity and geographical area and 
the growth rates over the period of the different categories of 
investments (manufacturing, R&D and others) are presented 
in Table 6.1. 
Greenfield FDIs in manufacturing activities represent the 
highest share, both in terms of value (60% of total capital 
investments) and number of projects (39%). The shares for 
FDIs on R&D are 5% and 12% respectively. 
Table 6.1 Decomposition of FDIs by activity
Source Region Outflows (% € 2030 bn)
Projects (% 
of 27208)
Destination
Region
Inflows (% € 
2030 bn)
Projects (% 
of 27208)
Asian Tigers 7 4 Asian Tigers 5 6
BRICS 7 4 BRICS 34 34
EU 42 36 EU 9 17
Japan 14 19 Latin America 8 6
RoW 2 2 RoW 18 13
Switzerland 2 4 South Asia 17 14
USA 25 30 USA 8 10
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD.
FDI type N. of projects € bn
Manufacturing 10514 1219
Sales & Marketing 4311 36
Research & Development 3342 97
Retail 2035 42
Logistics, Distribution & Transport. 1270 83
Business Services 1229 31
Headquarters 1086 29
Maintenance & Services 559 8
ICT & Internet Infrastructure 540 80
Education & Training 475 5
Extraction 474 254
Customer Contact 352 3
Electricity 343 110
Technical Support 277 3
Shared Services 228 4
Construction 123 24
Recycling 50 2
Total 27208 2030
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Looking at the geographical distribution, top EU R&D 
investors appear as the main source of greenfield FDIs, both 
in terms of value (42% of the total versus 25% for their US 
counterparts) and of number of projects (36% versus 30% for 
US top R&D investors). These figures confirm the important 
role played by the EU as the main source of FDIs15. In terms 
of destination, BRICS countries (Brazil, Russia, India, China 
and South Africa) appear to be the main beneficiaries (34% 
of total value and 34% of the total number of projects). The 
15 Analysing a different sample, similar results have been reported by the “Foreign 
direct investment statistics” (Eurostat), http://epp.eurostat.ec.europa.eu/statistics_
explained/index.php/Foreign_direct_investment_statistics.
EU attracts 9% of the value and 17% of the projects (versus 
8% and 10% respectively for the US). 
Table 6.2 highlights the top 10 European (red) and non-
European (black) countries responsible for the larger shares 
of worldwide direct investment flows. The table reports the 
number of investment projects, estimated capital expenditure 
(in billions of Euro) and estimated number of jobs created (in 
thousands). 
Table 6.2 FDI outflows and inflows, 2003-2012
Top 10 source countries (86% of total n. of projects)
Source Region N. of projects € bn Jobs (x1000)
United States 8252 505 1808
Japan 5156 289 1437
Germany 3291 205 890
France 1672 164 440
UK 1526 131 392
Switzerland 1180 43 203
South Korea 769 96 364
Netherlands 662 99 157
Sweden 534 18 110
Italy 499 69 170
Top 10 destination countries (55% of total n. of projects)
Source Region N. of projects € bn Jobs (x1000)
China 4353 325 1522
United States 2618 166 410
India 2505 142 902
Russia 1162 81 366
Brazil 980 131 411
UK 817 29 95
Singapore 681 44 114
Mexico 660 54 268
Canada 616 72 96
Thailand 613 26 205
Source: The 2013 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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The two top investing countries are the US and Japan, 
followed by a set of EU countries: Germany, France, and the 
UK. Also, the last three top 10 investing countries are the 
Netherlands, Sweden, and Italy.
In contrast, the top destination countries are the emerging 
economies of China, India, Russia, and Brazil, and the US 
(in second place). The estimated number of jobs that are 
expected to be created by the FDI projects is proportionate 
to their magnitude. Moreover, most of the jobs are estimated 
to be created by US projects and expected to be created in 
China.
Locating R&D abroad: how attractive is the EU for 
greenfield FDI?
Table 6.3 shows the flows of FDI in R&D from region to region. 
BRICS and European countries are the most attractive: top 
R&D investors locate 41% of their total number of FDIs in 
R&D in the BRICS and 22% in the EU (we exclude in this 
account intra-EU flows, to make it comparable with other 
world regions). In comparison, the US receives only 8 % of 
R&D projects. Considering the geographical location of the 
companies performing such FDI in R&D, 26% of the projects 
originate in Europe, 11% in Japan, and 52% in the US.  
Table 6.3: Flows of FDIs in R&D, 2003-2012 (% of n. of projects)
Destination Region
Source 
Region
Asian 
Tigers BRICS EU Latin Am RoW
South 
Asia USA Total
Asian 
Tigers 0.09 1.65 0.57 -  0.18 0.12 0.72 3.32 
EU 2.60 12.39 -   0.84 3.05 2.12 4.61 25.61 
Japan 1.38 3.92 2.63 0.03 0.33 1.14 2.03 11.46 
RoW 0.03 0.39 0.51 0.03 0.15 -   0.15 1.26 
Switzerland 0.42 1.32 1.20 0.09 0.45 0.03 0.51 4.01 
USA 4.61 20.89 15.83 1.94 4.67 3.83 -   51.77 
BRICS 0.09 0.48 1.11 0.18 0.33 0.18 0.21 2.57 
Total 9.22 41.02 21.84 3.11 9.16 7.42 8.23 3,342
Source: The 2013 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Table 6.4 displays in more detail the destination of the 856 
FDI projects in R&D made by the EU Scoreboard companies 
during the period 2003-2012. The main destinations are 
the BRICS (49% of projects and 48% of the total capital 
investment) and the US (18% and 21%, respectively). 
Table 6.5 mirrors the same exercise, analysing the inflows of 
R&D projects undertaken by non-EU Scoreboard companies 
into EU countries. The vast majority of the total number of 
projects comes from US companies (72%), and from Japan 
(12%). Similar figures are found for capital expenditure (73% 
and 10% of €16.2bn, respectively). 
Table 6.4: Where do EU Companies locate R&D investment?
Source N. of projects Capex (€ bn)
USA 1730 48.8
EU 856 25.4
Japan 383 8.2
Switzerland 134 6.6
Asian Tigers 111 3.8
BRICS 86 3.1
RoW 42 0.9
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD.
➮
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Figure 6.6 compares the inflows and outflows of FDIs in R&D 
and manufacturing, across geographical areas. The top two 
pie charts report the percentages of the total number of 
project outflows, while the bottom pie charts represent the 
inflows, as a percentage of projects. Comparing R&D inflows 
and outflows, figures show that the EU has a more balanced 
account (4% net outflow) than the US (44% net outflow). If 
we compare the inflow shares of the two types of projects, 
manufacturing and R&D, we observe that the EU has a larger 
share of the more knowledge-intensive projects (R&D) than 
resource-saving investments (manufacturing). Concretely, 
the difference between these two shares is 7%, larger than 
for any other world region (BRICS 1%, Asian Tigers 5%, RoW 
0%, USA -3%, South Asia -6%, and Latin America -4%). 
Table 6.5: From which companies do EU receive FDI in R&D?
Source N. of projects Capex (€ bn)
BRICS 1371 44.4 
EU 730 16.2
USA 308 9.6
RoW 306 9.0
Asian Tigers 275 8.6
South Asia 248 5.2
Latin America 104 3.8
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD.
➮
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Sector distribution of FDIs in R&D
The identification of the key industrial sectors in which the top 
R&D spenders of the Scoreboard allocate their investments 
abroad has been made on the basis of a sample of companies 
for which data is available for the period 2003-2012. 
Figure 6.7 reports the number of projects by type of FDI 
(R&D versus manufacturing and other types of FDIs16) 
and R&D intensity (high, medium-high, medium-low, and 
low R&D intensity, see Box 1.1). The quasi totality (94%) 
16 The other types of FDIs are: sales & marketing, retail, logistics, distribution & 
transportation, business services, headquarters activities, maintenance & services, 
ICT & internet infrastructures, education & training, extraction, customer contact, 
electricity, technical support, shared services, construction, recycling.
of FDI projects in R&D from US companies are performed 
by companies from high and medium-high R&D intensity 
sectors. This confirms the importance of such investments 
as drivers for knowledge enhancement. In the EU, this 
percentage reduces to 83%. EU companies have a larger 
number of projects in manufacturing compared to the US 
(nearly 3.5 versus 2.6 thousand). Most of the projects come 
from companies belonging to medium-high and low R&D 
intensity sectors (67% and 20%, respectively) for the EU and 
medium-high and high ones (65% and 21%, respectively) for 
the US. The other types of FDIs exhibit diverging directions, 
with the bulk of EU projects originating from medium-low and 
low R&D-intensive sectors (54%), while the vast majority of 
US projects (90%) come from companies belonging to high 
and medium-high ones. 
Figure 6.6: Inflows and outflows of FDIs in R&D and manufacturing by region, 2003-2012
Source:  The 2013 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
T h e  2 0 1 3  E U  I n d u s t r i a l  R & D  I n v e s t m e n t  S c o r e b o a r d
60
In general, these figures confirm the strategic importance of 
FDIs for firms operating in more intensive R&D sectors. 
Figure 6.8 reports on the industries and regions that 
originate the highest volumes of FDI capital expenditure 
in R&D activities. As the graph shows, most of the 
investments in R&D (60% of the total capital investment of 
€97.0bn) are concentrated in ICT (production and services), 
Pharmaceuticals & Biotechnology, and Automobiles & Parts. 
These results are in line with the findings of another recent 
study from the European Commission17, which reports 
evidence on how foreign innovation-related activities, 
including R&D are heavily concentrated in terms of sectors.
17 “The role and internationalisation strategies of multinational companies in 
innovation”, 2013 DG ENTR http://ec.europa.eu/enterprise/policies/innovation/files/
proinno/innovation-intelligence-study-6_en.pdf
Figure 6.7: Number of FDI projects (2003-2012), by type and sector group.
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD.
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The main actors of this knowledge-seeking type of investment 
are the US and EU, Japan mainly for the automobiles industry 
and Switzerland for ICT production and Pharmaceuticals. 
This suggests that advanced economies are getting access 
to technological complementary knowledge by investing 
abroad.
Figure 6.8  R&D FDIs outflows by sector and region, 2003-2012 (€ bn)
Source: The 2013 EU Industrial R&D Investment Scoreboard,  European Commission, JRC/DG RTD.
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The Scoreboard is part of the European Commission’s 
monitoring activities to improve the understanding of trends 
in R&D investment by the private sector and the factors 
affecting it. It was created in response to the Commission’s 
Research Investment Action Plan18, which aims to help close 
the gap between the EU’s R&D investment and that of other 
developed economies.
The annual publication of the Scoreboard is intended to raise 
awareness of the importance of R&D for businesses and to 
encourage firms to disclose information about their R&D 
investments and other intangible assets.
The data for the Scoreboard are taken from companies’ 
publicly available audited accounts. As in more than 99% 
of cases these accounts do not include information on the 
place where R&D is actually performed, the company’s 
whole R&D investment in the Scoreboard is attributed to the 
country in which it has its registered office19. This should be 
borne in mind when interpreting the Scoreboard’s country 
classifications and analyses. 
The Scoreboard’s approach is, therefore, fundamentally 
different20 from that of statistical offices or the OECD when 
preparing Business Enterprise Expenditure on R&D (BERD) 
data, which are specific to a given territory. The Scoreboard 
data are primarily of interest to those concerned with 
benchmarking company commitments and performance (e.g. 
companies, investors and policymakers), while BERD data are 
primarily used by economists, governments and international 
organisations interested in the R&D performance of territorial 
units defined by political boundaries. The two approaches are 
therefore complementary. The methodological approach of 
18 “Investing in research: an action plan for Europe”, COM(2003)266, http://europa.
eu.int/eur-lex/en/com/cnc/2003/com2003_0226en02.pdf. 
19 The registered office is the company address notified to the official company 
registry. It is normally the place where a company’s books are kept.
20 The Scoreboard refers to all R&D financed by a company from its own funds, 
regardless of where the R&D is performed. BERD refers to all R&D activities performed 
by businesses within a particular sector and territory, regardless of the location of 
the business’s headquarters, and regardless of the sources of finance. The sources 
of data also differ: the Scoreboard collects data from audited financial accounts and 
reports whereas BERD typically takes a stratified sample, covering all large companies 
and a representative sample of smaller companies. Additional differences concern the 
definition of R&D intensity (BERD uses the percentage of R&D in value added, while 
the Scoreboard considers the R&D/Sales ratio) and the sectoral classification (BERD 
uses NACE (the European statistical classification of economic sectors), while the 
Scoreboard uses the ICB (the International Classification Benchmark).
the Scoreboard, its scope and limitations are further detailed 
in Annex 2 below.  
Scope and target audience
The Scoreboard is a benchmarking tool which provides 
reliable up-to-date information on R&D investment and 
other economic and financial data, with a unique EU-focus. 
The 2000 companies listed in this year’s Scoreboard account 
for more than 90%21 of worldwide business enterprise 
expenditure on R&D (BERD). The data in the Scoreboard are 
published as a four-year time-series to allow further trend 
analyses to be carried out, for instance, to examine links 
between R&D and business performance.
The Scoreboard is aimed at three main audiences. 
• Companies can use the Scoreboard to benchmark 
their R&D investments and so find where they stand in 
the EU and in the global industrial R&D landscape. This 
information could be of value in shaping business or R&D 
strategy. 
• Investors and financial analysts can use the Scoreboard 
to assess investment opportunities and risks.
• Policy-makers, government and business 
organisations can use R&D investment information as an 
input to policy formulation or other R&D-related actions. 
Furthermore, the Scoreboard dataset has been made freely 
accessible so as to encourage further economic and financial 
analyses and research by any interested parties.
21 According to latest Eurostat statistics. However BERD and Scoreboard figures are 
not directly comparable.
Annex 1 - Background information
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The data for the ranking of the 2013 EU Industrial R&D 
Scoreboard (the Scoreboard) have been collected from 
companies’ annual reports and accounts by Bureau van Dijk 
Electronic Publishing GmbH (BvD). The source documents, 
annual reports & accounts, are public domain documents 
and so the Scoreboard is capable of independent replication. 
In order to ensure consistency with our previous Scoreboards, 
BvD data for the years prior to 2012 have been checked with 
the corresponding data of the previous Scoreboards adjusted 
for the corresponding exchange rates of the annual reports. 
Main characteristics of the data
The data correspond to companies’ latest published accounts, 
intended to be their 2012 fiscal year accounts, although due 
to different accounting practices throughout the world, they 
also include accounts ending on a range of dates between 
late 2011 and early 2013.  Furthermore, the accounts of 
some companies are publicly available more promptly than 
others. Therefore, the current set represents a heterogeneous 
set of timed data.
In order to maximise completeness and avoid double 
counting, the consolidated group accounts of the ultimate 
parent company are used. Companies which are subsidiaries 
of any other company are not listed separately. Where 
consolidated group accounts of the ultimate parent company 
are not available, subsidiaries are included.
In case of a demerger, the full history of the continuing entity 
is included. The history of the demerged company can only 
go back as far as the date of the demerger to avoid double 
counting of figures.
In case of an acquisition or merger, pro forma figures for 
the year of acquisition are used along with pro-forma 
comparative figures if available. 
The R&D investment included in the Scoreboard is the cash 
investment which is funded by the companies themselves. 
It excludes R&D undertaken under contract for customers 
such as governments or other companies. It also excludes 
the companies’ share of any associated company or joint 
venture R&D investment when disclosed. Where part or all 
of R&D costs have been capitalised, the additions to the 
appropriate intangible assets are included to calculate the 
cash investment and any amortisation eliminated.
Companies are allocated to the country of their registered 
office. In some cases this is different from the operational 
or R&D headquarters. This means that the results are 
independent of the actual location of the R&D activity. 
Companies are in industry sectors according to the NACE 
Rev. 222 and the ICB (Industry Classification Benchmark).
Limitations
The Scoreboard relies on disclosure of R&D investment 
in published annual reports and accounts. Therefore, 
companies which do not disclose figures for R&D investment 
or which disclose only figures which are not material enough 
are not included in the Scoreboard. Due to different national 
accounting standards and disclosure practice, companies of 
some countries are less likely than others to disclose R&D 
investment consistently. 
In some countries, R&D costs are very often integrated with 
other operational costs and can therefore not be identified 
separately. For example, companies from many Southern 
European countries or the new Member States are under-
represented in the Scoreboard. On the other side, UK 
companies are over-represented in the Scoreboard. 
For listed companies, country representation will improve 
with IFRS adoption.
The R&D investment disclosed in some companies’ accounts 
follows the US practice of including engineering costs 
relating to product improvement. Where these engineering 
costs have been disclosed separately, they have been 
excluded from the Scoreboard. However, the incidence of 
non-disclosure is uncertain and the impact of this practice is 
a possible overstatement of some overseas R&D investment 
figures in comparison with the EU. 
Where R&D income can be clearly identified as a result of 
customer contracts it is deducted from the R&D expense 
stated in the annual report, so that the R&D investment 
included in the Scoreboard excludes R&D undertaken under 
contract for customers such as governments or other 
22 NACE is the acronyme for “Nomenclature statistique des activités économiques 
dans la Communauté européenne”.
Annex 2 - Methodological notes
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companies. However, the disclosure practise differs and R&D 
income from customer contracts cannot always be clearly 
identified.  This means a possible overstatement of some 
R&D investment figures in the Scoreboard for companies 
with directly R&D related income where this is not disclosed 
in the annual report.
In implementing the definition of R&D, companies exhibit 
variability arising from a number of sources: i) different 
interpretations of the R&D definition. Some companies view 
a process as an R&D process while other companies may 
view the same process as an engineering or other process; ii) 
different companies’ information systems for measuring the 
costs associated with R&D processes; iii) different countries’ 
fiscal treatment of costs.
Interpretation
There are some fundamental aspects of the Scoreboard 
which affect their interpretation.
The focus of the Scoreboard on R&D investment as reported 
in group accounts means that the results can be independent 
of the location of the R&D activity. The Scoreboard indicates 
the level of R&D funded by companies, not all of which is 
carried out in the country in which the company is registered. 
This enables inputs such as R&D and Capex investment to 
be related to outputs such as Sales, Profit, productivity ratios 
and market capitalisation. 
The data used for the Scoreboard are different from data 
provided by statistical offices, e.g. BERD data. The Scoreboard 
refers to all R&D financed by a particular company from 
its own funds, regardless of where that R&D activity is 
performed. BERD refers to all R&D activities performed by 
businesses within a particular sector and territory, regardless 
of the location of the business’s headquarters, and regardless 
of the sources of finance. 
Further, the Scoreboard collects data from audited financial 
accounts and reports. BERD typically takes a stratified 
sample, covering all large companies and a representative 
sample of smaller companies. Additional differences concern 
the definition of R&D intensity (BERD uses the percentage of 
value added, while the Scoreboard measures it as the R&D/
Sales ratio) and the sectoral classification they use (BERD 
follows NACE, the European statistical classification of 
economic sectors, while the Scoreboard classifies companies’ 
economic activities according to the ICB classification).
Sudden changes in R&D figures may arise because a change 
in company accounting standards. For example, the first time 
adoption of IFRS23, may lead to information discontinuities 
due to the different treatment of R&D, i.e. R&D capitalisation 
criteria are stricter and, where the criteria are met, the 
amounts must be capitalised. 
For many highly diversified companies, the R&D investment 
disclosed in their accounts relates only to part of their 
activities, whereas sales and profits are in respect of all their 
activities. Unless such groups disclose their R&D investment 
additional to the other information in segmental analyses, it 
is not possible to relate the R&D more closely to the results 
of the individual activities which give rise to it. The impact 
of this is that some statistics for these groups, e.g. R&D as 
a percentage of sales, are possibly underestimated and so 
comparisons with non-diversified groups are limited.
At the aggregate level, the growth statistics reflect the growth 
of the set of companies in the current year set. Companies 
which may have existed in the base year but which are 
not represented in the current year set are not part of the 
Scoreboard (a company may continue to be represented in 
the current year set if it has been acquired by or merged 
with another). 
For companies outside the Euro area, all currency amounts 
have been translated at the Euro exchange rates ruling at 
31 December 2012 as shown in Table A3.1.The exchange 
rate conversion also applies to the historical data. The 
result is that over time the Scoreboard reflects the domestic 
currency results of the companies rather than economic 
estimates of current purchasing parity results. The original 
domestic currency data can be derived simply by reversing 
the translations at the rates above. Users can then apply 
their own preferred current purchasing parity transformation 
models. 
 
23 Since 2005, the European Union requires all listed companies in the EU to prepare 
their consolidated financial statements according to IFRS (International Financial 
Reporting Standards, see: http://www.iasb.org/). 
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Table A3.1 Euro exchange rates applied to Scoreboard data of companies based in different currency areas 
(as of 31 Dec 2012).
Country As of 31 Dec 2011 As of 31 Dec 2012
Australia $ 1.2740 $ 1.27
Brazil 2.4051 Brazilian real 2.69 Brazilian real
Canada $ 1.3210 $ 1.31
China 8.1526 Renminbi 8.30 Renminbi
Czech Republic 25.7998 Koruna 25.14 Koruna
Croatia 7.5370 Kuna 7.55 Kuna
Denmark 7.4344 Danish Kronor 7.47 Danish Kronor
Hungary 314.158 Forint 291.54 Forint
India 68.9178 Indian Rupee 72.25 Indian Rupee
Israel 4.9439 Shekel 4.92 Shekel
Japan 100.6036  Yen 114.15  Yen
Mexico 18.10 Mexican Peso 17.16 Mexican Peso
Norway 7.750 Norwegian Kronor 7.35 Norwegian Kronor
Poland 4.4218 Zloty 4.09 Zloty
Russia 41.666 Rouble 40.08 Rouble
South Korea 1492.54 Won 1408.45 Won
Sweden 8.9119 Swedish Kronor 8.58 Swedish Kronor
Switzerland 1.2174 Swiss Franc 1.21 Swiss Franc
Turkey 2.450 Turkish lira 2.35 Turkish lira
UK £ 0.8368 £ 0.84
USA $ 1.2939 $ 1.32
Taiwan $ 39.1696 $ 38.28
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Glossary of definitions
1. Research and Development (R&D) investment in 
the Scoreboard is the cash investment funded by the 
companies themselves. It excludes R&D undertaken under 
contract for customers such as governments or other 
companies. It also excludes the companies’ share of any 
associated company or joint venture R&D investment. 
Being that disclosed in the annual report and accounts, 
it is subject to the accounting definitions of R&D. For 
example, a definition is set out in International Accounting 
Standard (IAS) 38 “Intangible assets” and is based on the 
OECD “Frascati” manual. Research is defined as original 
and planned investigation undertaken with the prospect 
of gaining new scientific or technical knowledge and 
understanding. Expenditure on research is recognised 
as an expense when it is incurred. Development is the 
application of research findings or other knowledge to a 
plan or design for the production of new or substantially 
improved materials, devices, products, processes, systems 
or services before the start of commercial production or 
use. Development costs are capitalised when they meet 
certain criteria and when it can be demonstrated that the 
asset will generate probable future economic benefits. 
Where part or all of R&D costs have been capitalised, the 
additions to the appropriate intangible assets are included 
to calculate the cash investment and any amortisation 
eliminated.
2. Net sales follow the usual accounting definition of 
sales, excluding sales taxes and shares of sales of joint 
ventures & associates. For banks, sales are defined as 
the “Total (operating) income” plus any insurance income. 
For insurance companies, sales are defined as “Gross 
premiums written” plus any banking income.
3. R&D intensity is the ratio between R&D investment and 
net sales of a given company or group of companies. At 
the aggregate level, R&D intensity is calculated only by 
those companies for which data exist for both R&D and net 
sales in the specified year. The calculation of R&D intensity 
in the Scoreboard is different from that in official statistics, 
e.g. BERD, where R&D intensity is based on value added 
instead of net sales. 
4. Operating profit is calculated as profit (or loss) before 
taxation, plus net interest cost (or minus net interest 
income) minus government grants, less gains (or plus 
losses) arising from the sale/disposal of businesses or 
fixed assets.
5. One-year growth is simple growth over the previous 
year, expressed as a percentage: 1 yr growth = 100*((C/B)-
1); where C = current year amount, and B = previous year 
amount. 1yr growth is calculated only if data exist for both 
the current and previous year. At the aggregate level, 1yr 
growth is calculated only by aggregating those companies 
for which data exist for both the current and previous year.
6. Three-year growth is the compound annual growth over 
the previous three years, expressed as a percentage: 3 
yr growth = 100*(((C/B)^(1/t))-1); where C = current year 
amount, B = base year amount (where base year = current 
year - 3), and t = number of time periods (= 3). 3yr growth 
is calculated only if data exist for the current and base 
years. At the aggregate level, 3yr growth is calculated only 
by aggregating those companies for which data exist for 
the current and base years.
7. Capital expenditure (Capex) is expenditure used by a 
company to acquire or upgrade physical assets such as 
equipment, property, industrial buildings. In accounts 
capital expenditure is added to an asset account (i.e. 
capitalised), thus increasing the asset’s base. It is disclosed 
in accounts as additions to tangible fixed assets.
8. Number of employees is the total consolidated average 
employees or year end employees if average not stated.
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The 2013 Scoreboard comprises two data samples:
• The world’s top 2000 companies that invested more than 
€22.6m in R&D in 2012.
• The top 1000 R&D investing companies based in the EU 
with R&D investment exceeding €5.2m.
For each company the following information is available: 
• Company identification (name, country of registration and 
sector of declared activity according to ICB classifications).
• R&D investment 
• Net Sales 
• Capital expenditure 
• Operating profit or loss 
• Total number of employees
• Main company indicators (R&D intensity, Capex intensity, 
Profitability)
• Growth rates of main indicators over one year and three 
years.
The following links provide access to the two Scoreboard 
data samples containing the main economic and financial 
indicators and main statistics over the past four years.
R&D ranking of world top 2000 companies: http://iri.
jrc.ec.europa.eu/documents/10180/cf102ca1-e554-46d2-
b271-1168e83a419c
R&D ranking of EU top 1000 companies:  http://iri.jrc.
ec.europa.eu/documents/10180/64449b4f-9c6f-41a1-
9dcc-73183d84d17b
Annex 4 - Access to the full dataset
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Abstract
This report presents the results of the 2013 “EU Industrial R&D Investment Scoreboard” (the Scoreboard). The Scoreboard contains 
economic and financial data for the world’s top 2000 companies ranked by their investments in research and development 
(R&D). The sample consists of 527 companies based in the EU and 1473 companies based elsewhere. An additional sample 
comprising the top 1000 R&D investing companies based in the EU is included. The Scoreboard data are drawn from the latest 
available companies’ accounts, i.e. usually the fiscal year 2012 or 2012/13.
In this Scoreboard edition, world top R&D investors show a remarkable resilience of R&D investment growth in a period of 
economic uncertainty. In 2012, companies continued to increase significantly their R&D investments in a context marked by a 
slow-down of net sales growth and a decline in operating profits.
Trends observed show a significant variation of R&D investment and economic results across industries and sectors. This 
reflects persistent market uncertainties, in particular regarding the uneven potential for growth of international markets and the 
macroeconomic background.
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As the Commission’s in-house science service, the Joint Research Centre’s mission is to provide EU policies with independent, 
evidence-based scientific and technical support throughout the whole policy cycle.
Working in close cooperation with policy Directorates-General, the JRC addresses key societal challenges while stimulating 
innovation through developing new standards, methods and tools, and sharing and transferring its know-how to the 
Member States and international community.
Key policy areas include: environment and climate change; energy and transport; agriculture and food security; health and 
consumer protection; information society and digital agenda; safety and security including nuclear; all supported through 
a cross-cutting and multidisciplinary approach.
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